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 Microorganisms are an invaluable source of natural products. As humans, we 
have taken advantage of these small molecules to improve overall human health and 
quality of life. However, the rise in the number of pathogens that have become resistant 
to modern medicines requires action to deliver new compounds to treat disease. Natural 
products are a rich source of potential drug leads, as approximately 65% of our current 
antimicrobials are natural products or inspired by natural products. With the advent of 
genome sequencing, we now have the ability to quickly identify new biosynthetic gene 
clusters with the capacity to produce new natural products and quickly identify the genes 
required for the production of a natural product. Characterization of these biosynthetic 
gene clusters allow us to identify the enzymes required for the biosynthesis and 
functionalization of these compounds and the enzymes that may be used for inactivation 
of toxic compounds. They also inform us on strategies that can be used to manipulate 
these organisms to produce derivatives of potentially useful natural products.  
Among the most useful natural products are the phosphonic acids, which contain 
a carbon-phosphorus bond. Over the years, these small molecules have shown great 
success as drugs and herbicidal compounds, thus it is prudent to facilitate the rapid 
discovery and characterization of new phosphonate natural products. The work in this 
thesis focuses on the characterization of the enzymes needed for formation and 
functionalization of many different phosphonic acid biosynthetic pathways. 
Non-heme iron-dependent oxygenases are important enzymes in all domains of 
life that catalyze various chemical reactions involving the functionalization of an un-
activated carbon atom. These enzymes are present in many phosphonate biosynthetic 
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pathways. Chapter 2 will focus on the in vitro biochemical characterization of the TauD-
family dioxygenases that are involved in the biosynthesis of dehydrophos, a compound 
with proven antibiotic activity, fosfazinomycin, a compound containing a unique 
phosphono-hydrazide linkage, and hydroxyphosphonocystoximate, a phosphonate 
containing an unusual thiohydroximate moiety. Here, I show that these enzymes share 
little identity with one another, which drive the substrate specificity of these oxygenases.  
Oxime-containing natural products are uncommon in nature, with even less being 
understood about how organisms make these functional groups. Phosphonocystoximic 
acid and its hydroxylated congener, hydroxyphosphonocystoximic, are two phosphonate 
natural products containing a free oxime moiety. Chapter 3 will focus on the enzymes 
required for N-oxidation and oxime formation during the biosynthesis of these two 
natural products. We have identified an NADPH- and FAD-dependent enzyme 
responsible oxidation of a primary amine to the oxime that is catalyzed early in the 
biosynthesis of these natural products. 
Phosphonothrixin is a potent herbicidal natural product that is produced by 
Saccharothrix sp. ST-888. Until recently, the biosynthetic gene cluster responsible for 
production of this compound remained elusive. I will describe in vitro characterization of 
three enzymes encoded within the phosphonothrixin biosynthetic gene cluster in Chapter 
4. Additionally, the isolation of dihydroxypropylphosphonic acid from culture extracts of 
Saccharothrix sp. ST-888 have allowed us to formulate a hypothesis for the biosynthesis 
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Chapter 1: Introduction to phosphonic acid natural products 
1.1 INTRODUCTION 
1.1.1 Importance of natural products in medicine 
Human lives have been influenced through the use of natural products for 
centuries. There is documentation from cultures around the world that date back as early 
as 2600 BC supporting the use of natural products to benefit human life (24, 54). From 
ancient herbal remedies to modern medicines, our lives would look vastly different 
without the influence of compounds isolated from natural sources. Currently, nearly two-
thirds of drugs used therapeutically are inspired by natural products, with upwards of 
80% of antibacterials being natural products or derivatives of natural compounds (102). 
Discovery of novel drugs with new targets is prudent as the number of antimicrobial-
resistant pathogens is continuously rising, presenting a severe burden to healthcare 
around the world (95, 114, 134).  
1.1.2 Natural product discovery in the genomics era 
 Development of new technologies for genome sequencing has driven the cost of a 
genome down and increased the quality of data received within the past decade (35). This 
has helped drive the exponentially growing number of sequences that have been 
deposited into GenBank (8). Genome sequencing of Streptomyces coelicolor A3(2) was 
instrumental to understanding actinobacterial potential for natural product production (9, 
15). We now understand that most actinobacteria can produce over 25 different natural 
products each (15). With the growing body of knowledge about how different natural 
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product classes are biosynthesized, we can rapidly dereplicate and prioritize organisms 
for the potential to produce novel natural products. 
1.2 PHOSPHONIC ACID NATURAL PRODUCTS 
 Phosphonic acids are reduced phosphorus small molecules containing direct 
carbon-phosphorus (C-P) bond, while phosphinic acids are defined as having a C-P-C or 
C-P-H bond. These molecules are known to be potent enzyme inhibitors due to molecular 
mimicry to phosphate esters, carboxylic acids, and tetrahedral intermediates in numerous 
metabolic pathways (93).  
1.2.1 Phosphonic acids in agriculture and medicine 
 The agriculture industry would look vastly different without the success of 
phosphonates. Glyphosate, which goes by the trade names RoundUp®, Rodeo®, 
Accord®, Touchdown®, and Shackle®, is a widely used herbicide. This synthetic 
phosphonate targets enolpyruvylshikimate-3-phosphate (EPSP) synthase, which is part of 
the shikimate pathway of aromatic amino acid biosynthesis (127). A natural product 
phosphinate that has found renowned success as an herbicide is phosphinothricin, 
trademarked under the names Finale®, Basta®, and Liberty®. This compound mimics 
the tetrahedral intermediate of glutamine synthase (32). The last phosphonate that has 
shown success is ethephon. This compound is used as a ripening agent, as ethephon is 
metabolized into ethylene within the plant (12). Fig 1.1 shows the different phosphonate 
natural products used as herbicidal compounds.  
 Many phosphonate compounds have importance as medicines as well. The 
synthetic bisphosphonate, alendronic acid (trade named Fosamax®), is one of the most 
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widely prescribed drugs used to treat osteoporosis (90). Many different phosphonates are 
nucleotide mimics used as antiviral compounds, such as tenofovir (antiretroviral used for 
HIV treatment) (7, 30), adefovir (reverse transcriptase inhibitor used for hepatitis B 
treatment) (22, 23, 110), and cidofovir (DNA polymerase inhibitor of cytomegalovirus) 
(22, 142). Fosinopril is the only clinically-approved phosphonate for the use as an 
angiotensin converting enzyme (ACE) inhibitor to treat hypertension (40, 137). A small 
number of phosphonate natural products also have important uses clinically. Fosfomycin, 
known by the trade name Monurol®, targets cell wall biosynthesis of Gram negative 
pathogens and is widely used for the treatment of urinary tract infections in women (28, 
29, 144, 149). Fosmidomycin on the other hand has shown promise in clinical trials for 
use in the treatment of malaria. This compound target DXP reductoisomerase involved in 
the non-mevalonate isoprenoid biosynthetic pathway of Plasmodium spp. (2, 76, 133). 





Figure 1.1. Phosphonic acids that are used clinically and agriculturally. The name of the 
phosphonate is listed below the structure, with the function of each compound listed 
below the name.  
1.2.2 Genome mining for novel phosphonate natural products 
 Given the clinical and agricultural applicability of phosphonates, it is prudent that 
we continue to invest time and resources to discover novel phosphonate natural products 
with new targets and functions. Discovery of novel phosphonate natural products is 
facilitated by the fact that all known phosphonate biosynthetic pathways, except for the 
structurally similar ACE inhibitors K-4 (72), K-26 (143), and I5B2 (65), start with the 
same biotransformation catalyzed by a single enzyme, phosphoenolpyruvate 
phosphomutase (PepM) (14, 44, 67, 120). PepM funnels the central metabolic 
intermediate, phosphoenolpyruvate (PEP), into secondary metabolism through the 
rearrangement of PEP to phosphonopyruvate, which is the first biosynthetic step 
catalyzing carbon-phosphorus bond formation.  
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Using pepM as a genetic handle, we are able to mine the genomes of sequenced 
organisms to identify those with the potential to produce novel phosphonate compounds 
(58, 59). We can distinguish bona fide PepM proteins from the related isocitrate lyase 
proteins through identification of a conserved active site motif, EDKxxxxxNS (16, 146). 
This same study also discovered that the degree of similarity between PepM amino acid 
sequences predicts the divergence of the phosphonate gene clusters, thus correlating the 
probability of discovering a new, undescribed phosphonate natural product with the 
sequence identity of PepM (146). Using this knowledge, a large study was done to screen 
for actinobacteria that have the genetic machinery to produce new phosphonate natural 
products (59). Close to 10,000 actinobacteria were analyzed for the presence of the pepM 
gene. Those pepM
+
 isolates were genome sequenced because the genes required for most 
bacterial natural products are clustered together on the genome (92, 109, 130). Thus, this 
quickly allowed for the identification of the putative phosphonate gene clusters in those 
organisms. Through this genome-mining effort, the number of phosphonate natural 
products reported in the literature nearly doubled, from 20 to 39 (59). 
This chapter will describe the discovery of different phosphonic acid natural 
products that have identified gene clusters and discuss the current understanding of how 
each of these natural products are made. This chapter is organized into sections based on 
common biosynthetic intermediates during biosynthesis: 2-aminoethylphosphonate, 2-





1.3 2AEP: THE FIRST DESCRIBED PHOSPHONATE AND A COMMON CELL-
WALL ASSOCIATED COMPOUND 
1.3.1 Physiological incorporation of 2AEP 
The first identified phosphonate natural product, 2-aminoethylphosphonic acid 
(2AEP), was discovered in 1959 and was isolated from a sheep rumen protozoan, 
Tetrahymena pyriformis (46). This natural product is arguably the most common 
phosphonate on Earth, as many different bacteria (5, 53, 136), fungi (135), protozoa (26, 
46, 64), and even invertebrates (61, 87, 88, 94, 112, 145)  produce 2AEP and incorporate 
it into lipid head groups (70) as glycerophosphonolipids and sphingnolipids (53, 61, 136). 
Interestingly, 2AEP has been isolated from bovine livers (39), while rat hepatocytes 
readily incorporate 2AEP as 1,2-diacylglyceryl-aminoethylphosphonate. Fig 1.2 shows 
the different phosphonic acids that have been isolated over the years from the cell 
membranes of different organisms. The exact physiological role of phosphonolipids in 
different organisms remains unknown, although the most logical explanation involves the 
stability of the C-P bond over the more labile carbon-oxygen-phosphorus (C-O-P) bond. 
In densely populated communities where phospholipases may be abundantly produced 
and excreted, the stability of the C-P bond may give a producing organism a competitive 





Figure 1.2. Phosphonic acids commonly found associated with the cell wall of different 
microorganisms.   
1.3.2 The biosynthesis of 2AEP 
The biosynthesis of 2AEP is carried out through three enzymatic transformations 
outlined in Fig 3. Prior to isolation of the enzymes required for this biotransformation, the 
Dunaway-Mariano group elucidated the biosynthesis of 2AEP by incubating radiolabeled 
substrates with Tetrahymena pyriformis extracts (4). Isolation and characterization of 
each individual enzyme over the years has confirmed these initial labeling studies. As is 
common with almost all phosphonate biosynthetic pathways, the isomerization of 
phosphoenolpyruvate (PEP) to phosphonopyruvate (PnPy) through the action of PEP 
mutase (PepM) is the first conserved biosynthetic step (48, 67, 100, 115, 119, 121). This 
highly unfavorable reaction is driven forward by phosphonopyruvate (PnPy) 
decarboxylase to form phosphonoacetaldehyde (PnAA) (55, 99, 101, 119, 150). The 
enzyme, 2AEP aminotransferase, then catalyzes the formation of 2AEP from PnAA (17, 






Figure 1.3. The biosynthesis of 2-aminoethylphosphonic acid involves three enzymatic 
transformations.  
1.3.3 Beyond 2AEP as a structural phosphonic acid 
As discussed at the beginning of this review, 2AEP and derivatives are common 
head groups incorporated into phosphonolipids and phosphonoglycans (53, 53, 61, 61, 
64, 136, 145, 146). To date, 2AEP has only been characterized as part of modifications to 
the membranes of different organisms. This section will discuss the involvement of 2AEP 
in the biosynthesis of the newly described phosphonate, phosphonocystoximic acid and 
its hydroxylated congener along with the prospect of 2AEP being involved in the 
biosynthesis of the clinically relevant compound, fosmidomycin.  
1.3.3.1 Phosphonocystoximic acid and hydroxynitrilaphos discovery 
The phosphonic acids isolated from the culture broth of Streptomyces regensis 
NRRL WC-3744 were shown to be a collection of unique natural products. The first 
isolated cyanohydrin-containing phosphonate, hydroxynitrilaphos, was isolated from 
spent culture medium of S. regensis NRRL WC-3744 (19). In this same study, three other 
phosphonic acids were also isolated from the spent medium when the organism was 
grown on ISP4 medium: 2AEP, N-acetyl-2AEP and N-acetyl-1-hydroxy-2AEP. In a later 
study, hydroxyphosphonocystoximic acid was identified via high resolution mass 
spectrometry to be present in ISP4 extracts of S. regensis WC-3744 (59). Based on the 
compounds isolated from the spent media and the presence of particular genes within the 
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gene cluster, it is hypothesized that hydroxyphosphonocystoximic acid is biosynthesized 
in a manner similar to glucosinolates, a common plant natural product, starting from 
2AEP (Fig 1.4). 
1.3.3.2 Phosphonocystoximate biosynthesis may be reminiscent of glucosinolate 
biosynthesis 
Glucosinolates are small, amino acid derived natural products, most commonly 
produced by plants (33, 37). The biosynthesis of these small molecules begins with the 
oxidative decarboxylation of an amino acid, catalyzed by a cytochrome P450-dependent 
N-oxygenase to yield an aldoxime intermediate (33). The hydroxyphosphonocystoximic 
acid gene cluster from S. regensis NRRL WC-3744 contains the conserved three-gene set 
to produce 2AEP: a PEP mutase, a phosphonopyruvate decarboxylase, and a 2AEP 
aminotransferase (19, 34). 2AEP could serve as an analogous compound similar to an 
amino acid. As discussed in Chapter 3, I show the subsequent FAD- and NADPH-
dependent oxidation of 2AEP to yield the aldoxime, 2-hydroxyiminophosphonic acid 
(34), which would reflect the aldoxime formed in glucosinolate biosynthesis. In 
glucosinolate biosynthesis, the aldoxime is further oxidized through the action of a 
separate cytochrome P450-dependent enzyme to form an unstable aci-nitro or nitrile 
oxide that can react with a sulfur donor such as cysteine or glutathione(38). This S-
alkylthiohydroximate structure would then be reminiscent of 
hydroxyphosphonocystoximic acid (Fig 1.4). Streptomyces do not produce glutathione 
(56), therefore an alternative pathway to S-alkylation needs to be proposed. Mycothiol-
conjugated hydroxyphosphonocystoximic acid has been observed by high-resolution 
mass spectrometry, indicating that mycothiol is the likely N-acetylcysteine donor (59).   
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In contrast, cyanogenic glucosides are natural products also produced by plants in 
a similar fashion to glucosinolates (122). However, formation of an aci-nitro used as an 
acceptor for a S-alkylation, involves a cytochrome P450-dependent enzyme catalyzes 
oxidation of the aldoxime to the nitrile (122). This molecule would be reminiscent of 
hydroxynitrilaphos (Fig 1.4). There are no cytochrome P450-dependent enzymes encoded 
in the S. regensis NRRL WC-3744 phosphonate gene cluster; however, there are two 
oxidoreductases that have no assigned function (Fig 1.4) that could be responsible for the 
oxidation of 2-hydroximinophosphonic acid to yield either a aci-nitroethylphosphonic 
acid (glucosinolate biosynthesis analog) or hydroxynitrilaphos (cyanogenic glucoside 
biosynthesis analog) (59). The presence of hydroxynitrilaphos in culture extracts suggests 
that the natural product biosynthetic pathway may resemble cyanogenic glucoside 
biosynthesis. The presence of ATP-grasp homologs within the gene cluster further 
suggest that hydroxynitrilaphos may not be the final natural product, but rather a 
degradation product of a larger peptide (59). 
1.3.3.3 Differences in the phosphonocystoximate and hydroxynitrilaphos gene cluster 
Streptomyces sp. NRRL S-481 contains a similar gene cluster to S. regensis WC-
3744(34, 59), thus it is not surprising that the natural product produced by this organism 
is similar to hydroxynitrilaphos produced by S. regensis. The Streptomyces sp. NRRL S-
481 gene cluster is lacking a phosphonopyruvate decarboxylase homolog, therefore it is 
unknown how Streptomyces sp. NRRL S-481 produces 2AEP as an intermediate for 
oxime-formation. This organism is also lacking a non-heme iron and α-ketoglutarate-
dependent dioxygenase homolog, which is responsible for the hydroxylation of the 
carbon alpha to the phosphorus atom in hydroxyphosphonocystoximate biosynthesis (34). 
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In this regard, even though it is unknown how Streptomyces sp. NRRL S-481 produces 
2AEP, it is speculated that the biosynthesis will proceed in a similar manner to the 
pathway proposed in S. regensis NRRL WC-3744. 
 
Figure 1.4. (A) Gene clusters and putative function for each protein encoded by each 
putative ORF from Streptomyces sp. NRRL S-481 for phosphonocystoximate 
biosynthesis and Streptomyces regensis NRRL WC-3744 for 
hydroxyphosphonocystoximate and hydroxynitrilaphos biosynthesis. (B) Putative 
biosynthetic pathways for phosphonocystoximate (Pcx proteins) and 
hydroxyphosphonocystoximate (Hpx proteins). (C) Partial biosynthetic pathway of 
glucosinolates ending with the S-alkylthiohydroximate intermediate resembling the 






1.3.4 Fosmidomycin is a potent phosphonic acid with an unknown biosynthetic 
pathway 
1.3.4.1 Fosmidomycin discovery and bioactivity 
Fosmidomycin, first named FR-31564, was originally isolated from the 
fermentation broth of Streptomyces lavendulae No. 8006 (ATCC 31279) (52, 78, 106). A 
related, dehydrated compound, was isolated from the same organism and called FR-
32863 (52, 78, 106). Initial studies comparing the bioactivity of fosmidomycin and 
fosfomycin found that fosmidomycin showed bioactivity against a wide variety of Gram-
negative pathogens and only some Gram-positive organisms (97). Fosmidomycin showed 
equal to or greater antimicrobial activity against many different pathogens when 
compared to the bioactivity of gentamycin and fosfomycin, while in vivo efficacy of 
fosmidomycin was equal to fosfomycin for clearance of skin infections (97). 
 The original studies examining fosmidomycin mode of action noted that 
resistance only arose through transporter mutants, rather than physical inactivation of the 
molecule (73). This was different than the inactivation of fosfomycin, where 
phosphorylation is responsible for resistance to the antibiotic (71). However, studies 
investigating the mode of action of fosmidomycin discovered that the molecule inhibited 
carotenoid and menaquinone biosynthesis, suggesting the isoprenoid biosynthesis as the 
specific target (125). Indeed, fosmidomycin is a potent inhibitor of 1-deoxy-D-xylulose 
5-phosphate (DXP) reductoisomerase, a key step in the non-mevalonate isoprenoid 
biosynthetic pathway of both bacteria (82) and plants (57). The discovery that 
Plasmodium falciparum also uses the non-mevalonate isoprenoid biosynthetic pathway 
was critical for launching fosmidomycin into development as an antimalarial drug (57, 
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86). This process was accelerated because previous Phase I clinical trials had already 
demonstrated tolerance for fosmidomycin in humans as a potential antibiotic (75).  
1.3.4.2 Biosynthetic gene cluster of S. lavendulae No. 8006 
Even though fosmidomycin has reached Phase II human clinical trials for the 
treatment of malaria and different Gram-negative infections, how S. lavendulae No. 8006 
produces this bioactive molecule remains elusive. The putative phosphonate biosynthetic 
gene cluster was recently identified upon sequencing of the S. lavendulae No. 8006 
genome (59). The genes within the genomic neighborhood of the PEP mutase suggest 
that the biosynthetic pathway may proceed through the biosynthesis of 2AEP (Fig 1.3), 
due to the presence of a PnPy decarboxylase and a 2AEP aminotransferase homolog (Fig 
1.5). Beyond the presence of these homologs within the genomic neighborhood, little is 
known about the route to fosmidomycin in S. lavendulae No. 8006. 
 
Figure 1.5. Putative fosmidomycin biosynthetic gene cluster. The gene cluster contains 
homologs of the genes required for production of 2AEP, although how S. lavendulae 
produces fosmidomycin from 2AEP remains elusive. 
1.4 2HEP, AN INTERMEDIATE COMMON IN PHOSPHONOPEPTIDE 
BIOSYNTHETIC PATHWAYS 
 The first phosphonate biosynthetic pathways investigated after the discovery of 
2AEP did not include this small molecule as a biosynthetic intermediate, but rather a 
14 
 
different two-carbon molecule that is hydroxylated opposed to aminated.  This small 
molecule is derived from phosphoenolpyruvate in three enzymatic steps (Fig 1.6). PEP 
mutase and phosphonopyruvate decarboxylase catalyze the transformation of 
phosphoenolpyruvate to phosphonoacetaldehyde. A type-III iron-dependent alcohol 
dehydrogenase, PhpC, was originally identified in phosphinothricin biosynthesis to 
catalyze the reduction of phosphonoacetaldehyde to 2-hydroxyethylphosphonic acid 
(123, 124). Homologs of this enzyme were further identified as part of phosphonoglycan 
biosynthesis (147), fosfomycin biosynthesis (124, 141), dehydrophos biosynthesis (21), 
and phosphinothricin biosynthesis (124). 
 
Figure 1.6. The biosynthesis of 2-hydroxyethylphosphonic acid involves three enzymatic 
transformations.  
1.4.1 Phosphonoglycans 
As described in the previous section about 2AEP biosynthesis, phosphonic acids 
are common modifications for lipids, proteins, and glycans. Most of these modifications 
involve the use of 2AEP as the phosphonic acid. In this section, I will discuss the 
discovery and partial biosynthetic pathway involved in production of phosphonoglycans 
using 2HEP as the phosphonic acid.  
1.4.1.1 Production of phosphonoglycans in Glycomyces 
Glycomyces sp. strain NRRL B-16210 was shown to produce phosphonic acids at 
a high levels through analysis by 
31
P NMR spectroscopy (147). Degradation of the cell 
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walls using lysozyme increased the levels of phosphonates detected, indicating that the 
phosphonic acid was associated with the cell wall. After partial acid hydrolysis of the 
phosphonates isolated from the cells, both glycerol-attached (2-HEP mono(2,3-
dihydroxypropyl)ester) and hexose-linked (likely 2-HEP galactose) 2HEP derivatives 
were detected using 
31
P NMR spectroscopy and MS-MS fragmentation analysis of the 
compounds (147). The isolation of both glycerol-linked and hexose-linked phosphonic 
acids from one cell, suggested that these compounds may be part of a larger branched 
poly-teichoic acid cell wall present in different Gram-positive organisms, yet further 
experimentation is needed to demonstrate this (147).  
1.4.1.2 Phosphonoglycan biosynthetic pathway 
 The gene cluster for phosphonoglycan biosynthesis contains PepM and PnPy 
decarboxylase homologs, which would have the ability to generate PnAA. In an operon-
like organization with ppm and ppd, the gene cluster contains an iron-dependent alcohol 
dehydrogenase homolog that should form 2HEP. These are the only three genes that have 
homologs in other phosphonate biosynthetic pathways, thus seeing the production of 
2HEP is unsurprising. In addition to this three-gene cassette, within the genomic 
neighborhood, there are genes homologous to those involved in glycan biosynthesis and 
teichoic acid biosynthesis.  Therefore, the compounds isolated from Glycomyces sp. 
strain NRRL B-16210 likely are modifications to the cell membrane as 




Figure 1.7. The phosphonate biosynthetic gene clusters from Glycomyces sp. NRRL B-
16338 and Stackebrandtia nassuensis DSM 44728 and the natural products isolated from 
each strain.  
1.4.2 Fosfomycin: a phosphonate so important that nature invented two biosynthetic 
routes to the same product? 
1.4.2.1 Fosfomycin discovery and mode of action 
With regards to treating disease, fosfomycin is arguably the most important 





, this natural product is commonly used to treat urinary tract infections in the 
United States (28, 29, 113, 149). Fosfomycin targets cell wall biosynthesis in both Gram-
positive and Gram-negative organisms though the inhibition of phosphoenolpyruvate 
synthase (60, 96).  
This natural product was originally discovered in 1969 to be produced by 
Streptomyces wedmorensis and Streptomyces fradiae (129) and showed broad spectrum 
antimicrobial activity (41). Seventeen years later, fosfomycin was discovered again in a 
search for broad spectrum antibiotics in Pseudomonas syringae (126). Genome 
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sequencing of P. syringae PB-5123 in 2012 revealed that this strain did not contain the 
same phosphonate-specific genetic machinery as used by Streptomyces fradiae to 
produce fosfomycin (68, 141), yet both strains have been shown to produce the identical 
final product. Investigations into this natural product resulted in a nearly complete 
understanding of the biosynthesis of fosfomycin in Streptomyces, yet the biosynthetic 
route to fosfomycin awaits elucidation in Pseudomonads. I will outline the biosynthetic 
routes to the production of this clinically used phosphonate in both organisms.  
1.4.2.2 Biosynthesis of fosfomycin in Streptomyces 
The fosfomycin biosynthetic pathway in Streptomyces has nearly been pieced 
together to completion, with only one enzymatic transformation likely needing to be 
described. The fosfomycin gene cluster in Streptomyces consists of eight genes, six of 
which are likely involved in biosynthesis (18, 42, 43, 45, 68, 141), with the two 
remaining proteins, FomA and FomB, providing self-resistance to fosfomycin (71). The 
first committed step, catalyzed by the phosphoenolpyruvate mutase, Fom1, generates 
phosphonopyruvate (43), which can be decarboxylated to form phosphonoacetaldehyde 
(PnAA) using Fom2, the phosphonopyruvate decarboxylase homolog (42). FomC 
catalyzes the reduction of PnAA to 2-hydroxyethylphosphonic acid (2HEP) (124). For 
many years, the function of a methylcobalamin-dependent radical-SAM-dependent 
methyltransferase, Fom3, remained elusive (1, 80) , though it was predicted to form 2-
hydroxypropylphosphonic acid (2-HPP) by methylating 2HEP.  
Recently, it has been shown that Fom3 methylates cytidylyl-2-
hydroxyethylphosphonate (CMP-2HEP) at a much higher rate than 2HEP reported by 
Allen and colleagues (116).  This reaction produces an equal ratio of cytidylyl-2-
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hydroxypropylphosphonate (CMP-2HPP) diastereomers, suggesting that there is no 
stereoselectivity during the methylation of CMP-2HEP (116). Recently, Cho and 
colleagues have shown that like many other phosphonate biosynthetic pathways, 
fosfomycin biosynthesis proceeds through the cytidylation of an intermediate in the 
pathway (18). Fom1, the phosphoenolpyruvate phosphomutase homolog, has an extra N-
terminal domain that shares homology to a cytidylyltransferase. When this gene is 
knocked out, fosfomycin production is recovered when mutants are supplemented with 
2HPP, but are unable to be rescued when the mutants are supplemented with 2HEP, 
suggesting that this protein functions downstream of 2HEP production (18). This would 
suggest that Fom1 has two functions within fosfomycin biosynthesis: (1) as the carbon-
phosphorus bond forming enzyme (43) and (2) as a cytidylyltransferase acting on 2HEP 
(18). During in vitro analysis of a truncated Fom1 protein containing only the 
cytidylyltransferase domain, Cho and colleagues discovered that the N-terminal domain 
of Fom1 does indeed catalyze the cytidylation of 2HEP in a cytidine triphosphate (CTP)-
dependent and cobalt(II)-dependent fashion (18).  
Fom4, also known as HppE, is a non-heme, ferrous iron-dependent, alpha-
ketoglutarate independent oxygenase and peroxidase that catalyzes epoxidation of 2HPP 
(45, 91, 148). Depending on the substrate bound within the active site, HppE can either 
perform epoxidation of (S)-2HPP or oxidation of (R)-2HPP, yielding 2-
oxopropylphosphonate (2OPP) (107). 
This leaves one biosynthetic enzyme to finalize the fosfomycin biosynthetic 
pathway. It is still unknown how CMP-2HPP will lose its CMP moiety, however, the 
remaining gene (fomD) within the fosfomycin biosynthetic cluster likely will catalyze 
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this transformation. FomD is homologous to the phosphatase, SA1684, from 
Staphylococcus aureus. This enzyme cleaves nucleotide diphosphoates, thus, it is 
predicted that FomD may hydrolyze the CMP-2HPP bond, yielding a racemic mixture of 
2HPP (116). 
 
Figure 1.8. There have been two different pathways discovered to date for fosfomycin 
biosynthesis. (A) The biosynthetic gene cluster from Streptomyces (fom genes) involves 
the biosynthesis of 2HEP, while the biosynthetic gene cluster in Pseudomonas (psf genes) 
are shown. Homologous enzymes are highlighted with the same color. (B) The 
biosynthetic routes to fosfomycin. Solid arrows denote biosynthetic steps with confirmed 
activity, while dashed arrows denote proposed biosynthetic steps.  
1.4.2.3 Biosynthesis of fosfomycin in Pseudomonas shares three homologous enzymes 
with Streptomyces 
The Pseudomonas fosfomycin biosynthetic pathway is significantly less 
characterized. The fosfomycin gene cluster in Pseudomonas was assigned based on the 
heterologous expression of a fosmid containing a 22.5 kb insert with putative fosfomycin 
genes into a Pseudomonas strain unable to make phosphonates (68). Interestingly, only 
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three genes were identified to be homologous to the enzymes in S. wedmorensis and S. 
fradiae. Psf1 was identified and labeled as the PEP mutase homolog, while psf7 encodes 
a kinase homologous to fomA that is responsible for self-resistance through 
phosphorylation of fosfomycin (71). The final enzymatic step of fosfomycin biosynthesis, 
carried out by Psf4, is also shared with the Streptomyces pathway. Psf4 is a homolog of 
HppE and is responsible for the epoxidation of (S)-2-hydroxypropylphosphonic acid 
(2HPP) to yield fosfomycin. This reaction has been reconstituted in vitro (81, 98).  
1.4.2.4 Biosynthesis of fosfomycin in Pseudomonas shares homologous enzymes with 
other phosphonate biosynthetic pathways 
Unlike the Streptomyces pathway, P. syringae does not contain a 
phosphonopyruvate decarboxylase homolog to drive the highly unfavorable PEP mutase 
reaction forward through decarboxylation (55, 99, 119, 150). However, this pathway 
encodes a gene to produce Psf2, a citrate synthase-like protein homologous to FrbC in 
FR-900098 biosynthesis (27) and Pms in phosphinothricin biosynthesis (11, 118), which 
is responsible for the acetylation of phosphonopyruvate or phosphinopryruvate to form 
phosphonomethylmalic (PMM) acid or phosphinomethylmalic acid. Indeed, when Psf1 
and Psf2 are incubated with PEP in the presence of acetyl-CoA, PMM is the observed 
product (68).  
When Psf3, Psf5, Psf6, and Psf7 were heterologously expressed and activity was 
tested using PMM or 2HPP as substrates in vitro, no product was observed in any of 
these reactions, suggesting that these are not the native substrates of the enzymes or that a 
specialized cofactor or binding protein may be missing for the reactions (68). However, 
more recent studies have identified a function for Psf3 and have confirmed an additional, 
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hypothesized function for Psf4 (107). During the biosynthesis of fosfomycin in 
pseudomonads, 2-HPP was hypothesized to be derived from 2-oxopropylphosphonate (2-
OPP) through the reduction of 2-OPP by one of the two encoded dehydrogenases within 
the cluster, Psf3 or Psf6. Psf3 was found to be an NADPH-dependent reductase that 
forms (S)-2-HPP using 2-OPP as a substrate (107). When using (S)-2-HPP as the 
substrate in the presence of NADP
+
, but not (R)-2-HPP, 2-OPP was observed in the 
reaction mixture, confirming that (S)-2HPP is the product formed by Psf3. As discussed 
above, even though fosfomycin biosynthesis is not expected to proceed through the 
intermediate 2-OPP in Streptomyces, HppE has the ability to oxidize (R)-2-HPP to 2-OPP 
(148). During in vitro activities, Psf4, a homolog of HppE, was shown to have identical 
activities, thus, when a reaction mixture containing both Psf3 and Psf4 were incubated 
with a racemic mixture of 2-HPP, all of the product was converted to fosfomycin (107). 
The biosynthetic steps that can convert PMM to 2-HPP have yet to be identified. 
1.4.3 Dehydrophos, a compound with an elusive structure and unusual biosynthetic 
pathway 
1.4.3.1 Determination of the structure of dehydrophos 
Dehydrophos is a broad spectrum antimicrobial tripeptide isolated from the 
fermentation extracts of Streptomyces luridus NRRL 15101 originally discovered and by 
Eli Lily and Company in 1984 under the name A53868 (3). The original proposed 
structure, glycyl-leucyl-2-amino-2-propenyl-phosphonate, was reassigned in 1988 to 
A53868A, again by Eli Lily and Company (51) (Fig 1.9). In 2007, Whitteck and 
colleagues synthesized A53868A to confirm the structure of this compound and were 
surprised to find that it is not the compound produced by S. luridus NRRL 15101. The 
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new structure of A53868A was reassigned for a third time to dehydrophos (Fig 1.9), 
revealing the structure as an interesting O-methylated vinylphosphonic acid coupled to 
leucine and glycine (140). 
 
Figure 1.9. Original assignments of A53868 by Eli Lily and Company and final structure 
of dehydrophos. 
1.4.3.2 Antimicrobial activity of dehydrophos  
The broad-spectrum antimicrobial activity was originally reported by Johnson and 
colleagues at Eli Lily and Company and initial in vivo studies were done to show 
clearance of Salmonella typhimurium infected chickens (3). Later studies identified the 
importance of both the vinyl group and methylester on the bioactivity of dehydrophos 
(74), while Salmonella enterica knockout studies further investigated the mode-of-action 
of dehydrophos (21). Like many other Trojan horse antibiotics, the leucine-glycine 
dipeptide of dehydrophos is cleaved after import into the cell via the Opp peptide 
transporter. The peptidases, PepA and PepB, appear to be the major contributors to 
dehydrophos cleavage; however, PepD and PepN can supplement PepA and PepB 
mutants to maintain dehydrophos susceptibility. Upon in vitro cleavage of dehydrophos 
by PepA, methylacetylphosphonate was identified as a product of the reaction (21). This 
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molecule is a pyruvate mimic that has potent inhibitory effects on pyruvate 
dehydrogenase (103) and 1-deoxy-D-xylulose 5-phosphate (DXP) synthase (128).  
1.4.3.3 Biosynthesis of dehydrophos involves several unusual enzymatic steps 
The biosynthesis of dehydrophos is an interesting tale of unusual enzymology. 
The minimal 16 gene biosynthetic cluster for dehydrophos production was identified in 
2011 by Circello and colleagues using deletion mutants of a dehydrophos producing 
fosmid clone (21). The cluster includes genes homologous to those used to make 2HEPn 
(Fig 1.10): PepM (DhpE), phosphonopyruvate decarboxylase (DhpF), and a type-III iron-
dependent alcohol dehydrogenase (DhpG) (13, 21).  
An Fe(II)-dependent and α-ketoglutarate-dependent dioxygenase (DhpA) was 
found to hydroxylate the carbon alpha to the phosphorus atom of 2HEPn, yielding 
dihydroxyethylphosphonic acid (DHEP). It was proposed that the next three enzymatic 
steps of dehydrophos biosynthesis are related to serine biosynthesis in Escherichia coli 
(Fig 1.10) (21).  DHEP is a molecular mimic of glycerate, and DhpB was a predicted 
glycerate kinase homolog that was shown to phosphorylate DHEP on the distal hydroxyl 
group, similar to how glycerate kinase phosphorylates the hydroxyl group on the second 
carbon. DhpC, a phosphoglycerate dehydrogenase homolog was shown to oxidize 1-
hydroxy-2-phosphorylethylphosphonate (HP-EP) to 1-oxo-2-
phosphorylethylphosphonate (OP-EP) (20).  
DhpH is a two-domain protein, containing an aminotransferase domain (DhpH-N) 
and an oxidase domain (DhpH-C). It was initially proposed that DhpH-N would form 
amino-vinyl-phosphonic acid (ΔAla(P)), and this unstable intermediate would be 
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channeled to the active site of DhpH-C to catalyze the leuciyl-tRNA-dependent 
peptidyltransferase activity to attach leucine. However, when full length DhpH or DhpH-
N was incubated with pSer(P) and different keto-acids, OP-EP was not observed in the 
reaction, rather, acetylphosphonate was the sole product observed (13). Contrastingly, in 
2010, Circello and colleagues hypothesized that the PLP-dependent aspartate 
aminotransferase homolog, DhpD, would catalyze the aminotransferase reaction needed 
to form 1-amino-2-phosphorylethyl phosphonate (pSer(P)); however, in 2014, 
Bougioukou and colleagues showed that DhpD does not catalyze this transamination, 
rather DhpD catalyzes the transamination of acetylphosphonate to L-alanine-phosphonate 
(L-alaP) (21). 
 
Figure 1.10. Dehydrophos biosynthetic gene cluster from Streptomyces luridus 1510. 






1.4.4 Phosphinothricin is a commercially available herbicide 







. This compound mimics the tetrahedral 
intermediate of glutamine synthase (32) and is a potent herbicide due to inhibition of this 
critical enzyme required for nitrogen assimilation. Many crops have been engineered to 
contain the phosphinothricin acetyltransferase (pat) gene, which confers self-resistance of 
the producing organism to phosphinothricin. This means that farmers can grow crops that 
are resistant to phosphinothricin, however, the invading weeds, which are not resistant to 
this potent herbicide are killed upon treatment with phosphinothricin.  
1.4.4.1 Phosphinothricin: discovery of the different compounds with the same chemical 
warhead 
The biosynthetic logic (93, 117) and characterization of the unusual enzymology 
(111) of phosphinothricin biosynthesis have been covered in three reviews. Here, I will 
cover advances in the biosynthesis of phosphinothricin that were not covered in the 2009 
or 2013 reviews, including the sequencing and bioinformatic characterization of the 
bialaphos and phosalacine gene clusters (10), as well as the discovery and 
characterization of the desmethylphosphinothricin gene cluster (59).  
Phosphinothricin is the only described phosphinic acid natural product that 
contains a carbon-phosphorus-carbon bond, distinguishing it from the more common 
phosphonic acids, which have only one carbon-phosphorus bond. Phosphinothricin is 
commonly attached to amino acids to form a tripeptide that has been isolated from 
bacteria. A phosphinothricin tripeptide, which has phosphinothricin coupled to two L-
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alanine amino acids, was originally isolated from spent culture broth of Streptomyces 
viridochromogenes Tü494 (6) and Streptomyces hygroscopicus as SF-1293, later to be 
renamed bialaphos (104).  In 1984, phosalacine, in which phosphinothricin is coupled to 
alanine and leucine, was isolated from culture extracts from Kitasatospora phosalacinea 
KA-338 (108). Seven years later, the compound named trialaphos was isolated from S. 
hygroscopicus KSB-1285, was isolated as a tetrapeptide of phosphinothricin attached to 
three molecules of L-alanine (63). More recently, a compound has been isolated from 
Nonomureae sp. NRRL B-24552 that looks like phosphinothricin, but lacks amino acids 
coupled to the molecule. This natural product also has a hydrogen-phosphorus-carbon 
bond instead of the second carbon-phosphorus bond found in phosphinothricin. For these 
reasons, this newly isolated compound was called Desmethylphosphinothricin (59). 
1.4.4.2 Phosphinothricin biosynthesis involves nearly identical biosynthetic pathways 
for all producing organisms 
DNA sequencing of assorted plasmids helped determine the genes needed for 
phosphinothricin biosynthesis (11); however, complete sequencing of the S. 
viridochromogenes Tü494 bialaphos biosynthetic gene cluster was not completed until 
2005 (10, 118). Bioinformatic comparisons of the sequenced bialaphos (S. 
viridochromogenes Tü494 and S. hygroscopicus as SF-1293), phosalacine (K. 
phosalacinea KA-338), and desmethylphosphinothricin (Nonomureae sp. NRRL B-
24552) biosynthetic gene clusters revealed a common gene set that is involved in 
desmethylphosphinothricin biosynthesis, an intermediate involved in the biosynthesis of 
phosphinothricin (10, 59). Unlike the biosynthetic gene clusters in S. viridochromogenes 
Tü494 and S. hygroscopicus as SF-1293, the Nonomureae sp. NRRL B-24552 gene 
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cluster does not contain non-ribosomal peptide synthase genes that would be responsible 
for coupling phosphinothricin to other amino acids, nor does this gene cluster contain a 
homolog of PhpK, the radical-SAM-dependent methyltransferase responsible for 
methylation of desmethylphosphinothricin to form the second C-P bond (47, 59, 138). 
Therefore, it is likely that desmethylphosphinothricin may be the final product of this 
gene cluster (59).   
1.5 PHOSPHONOACETATE 
1.5.1 Fosfazinomycin: convergence of two small molecules to form one interesting 
phosphonic acid 
Fosfazinomycin is an unusual phosphonate natural product containing a 
phosphorus-hydrazide linkage. Compounds A and B, which differ in structure due to the 
presence (fosfazinomycin A) or absence (fosfazinomycin B) of valine, were originally 
isolated from the spent culture broth of Streptomyces lavendofoliae 630 (105). Antifungal 
activity, including hyphal swelling and branching abnormalities, was reported for 
fosfazinomycin (36).  
1.5.1.1 Discovery of the fosfazinomycin gene cluster 
The biosynthetic gene cluster for fosfazinomycin was identified using enzymatic 
modification of metabolites produced by Streptomyces sp. WM6372 using DhpI (31), the 
substrate-tolerable radical S- adenosylmethionine (SAM)-dependent O-methyltransferase 
that is responsible for methylester formation in dehydrophos (85). To do this, partially-
purified extracts were treated with DhpI, SAM, or CD3-labeled SAM. The chemical shifts 
of the two metabolites produced by Streptomyces sp. WM6372 changed after DhpI 
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treatment, suggesting modification of these molecules. The structure of these molecules 
were subsequently determined to be methyl phosphonoacetate (Me-PnA) and methyl 1-
hydroxyphosphonoacetate (Me-HPnA) (31). Upon recognition that Me-HPnA is a 
component of fosfazinomycin, extracts of Streptomyces sp. WM6372 were monitored 
using high resolution mass spectrometry for the presence of fosfazinomycin. 
Confirmation of the presence of fosfazinomycin in the extracts of Streptomyces sp. 
WM6372 allowed for the de-orphaning of the gene cluster responsible for 
fosfazinomycin production in not only Streptomyces sp. WM6372, but also in 
Streptomyces sp. XY332 (31) (Fig 1.11).  
1.5.1.2 Formation of fosfazinomycin requires convergence of two biosynthetic 
pathways 
Work by Huang and colleagues have determined that the biosynthesis of 
fosfazinomycin is different from most other phosphonic acids and involves the 
convergence of two different biosynthetic pathways to form one bioactive molecule (50). 
The first involves the biosynthesis of Me-HPnA, reminiscent of most phosphonate 
biosynthetic pathways (50). The second pathway involves the formation of a methylated 
hydrazide-containing arginine molecule (49, 50). The mechanism behind the linkage of 
these two molecules remains unsolved. I will discuss the formation of these two 
molecules in the following sections.  
1.5.1.3 Biosynthesis of methyl 1-hydroxyphosphonoacetate 
Elucidation of the biosynthetic pathway for Me-HPnA formation, starting from 
phosphonoacetaldehyde (PnAA), was completed through in vitro enzyme analysis. The 
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fosfazinomycin gene cluster contains nine genes in an operon-like organization (FzmA-I) 
that appears to be used to generate Me-HPnA (146). However, it appears as though only 
four of those genes are required for the formation of Me-HPnA. This cluster contains 
PepM and phosphonopyruvate decarboxylase homologs, which can generate 
phosphonoacetaldehyde. It is hypothesized that FzmG, a non-heme Fe(II)-dependent and 
2-oxoglutarate-dependent dioxygenase, may have dual-functions during the biosynthesis 
of fosfazinomycin (Fig 1.11). It was shown that FzmG will oxidize PnAA to PnA when 
incubated with ferrous iron and alpha-ketoglutarate. The same enzyme will also catalyze 
the hydroxylation of Me-PnA, forming Me-HPnA at ~1000-fold more efficiency than 
using PnA as a substrate, suggesting that an enzyme likely methylates PnA between the 
action of FzmG. This enzyme was identified to be FzmB, a radical SAM-dependent O-
methyltransferase. FzmB can use both PnA and HPnA with almost equal efficiency in 
vitro. Thus, the higher catalytic efficiency of FzmG towards Me-PnA suggests that FzmB 
acts after formation of PnA, but before hydroxylation of PnA (50).  
1.5.1.4 Biosynthesis of hydrazino-arginine 
Formation of the methylated hydrazide-containing arginine appears to be more 
complex. A second, ten-gene operon-like cassette (fzmJ-S) encoded directly downstream 
of fzmA-I, appears to be involved in N-N bond formation (49, 146). Labeling studies 
suggest that aspartic acid is used for N-N bond formation during the biosynthesis of 
fosfazinomycin, although aspartate is not part of the final molecule. A flavin-dependent 
N-oxidase, FzmM, was identified in the gene cluster which shares homology to the N-
oxidase involved in cremeomycin biosynthesis (131). FzmM activity was tested in vitro, 
and it was found that aspartic acid is readily oxidized to form nitrosuccinic acid, which 
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then spontaneously decarboxylates to form nitropropionic acid. Prior to this 
decarboxylation, the 3-carboxymuconate cycloisomerase homolog, FzmL, is proposed to 
generate nitrous acid and fumarate through the oxidation of nitrosuccinic acid. When 
aspartic acid is incubated in the presence of FzmM and FzmL, fumarate and nitrous acid 
are observed (49). It is still unknown as to how nitrous acid is added to aspartic acid to 
yield hydrazinosuccinate, but this is a suspected intermediate in fosfazinomycin 
biosynthesis due to hydrazinosuccinate being a substrate of the acetyltransferase, FzmQ. 
FzmR is an adenylosuccinate lyase homolog, that hydrolyzes N-acetylhydrazinosuccinate 
into acetylhydrazine and fumarate (49). It is unknown how the hydrazine moiety is added 
to arginine, but the radical SAM-dependent enzyme, FzmH, was shown to methylate 
hydrazino-arginine (50). FzmI, an aminoacyl-tRNA peptidyl transferase, can use 
arginine, hydrazino-arginine, methylhydrazino-arginine, and fosfazinomycin B as 
substrates (49). 
1.5.1.5 Joining the two small molecules into fosfazinomycin 
In total, most of the biosynthetic pathway of fosfazinomycin has been elucidated. 
However, arguably the most interesting biosynthetic steps await characterization: the 
formation of the nitrogen-nitrogen bond and the formation of the nitrogen-phosphorus 
bond. It is possible that comparative genomics may provide insights into the biosynthesis 
of these bonds. Another phosphorus-containing natural product has been identified that 
contains a phosphorohydrazate linkage. FR-900137 was purified from the culture extracts 
of Streptomyces unzenensis and shows antimicrobial activity against both Gram-positive 
and Gram-negative organisms (77). This molecule has structural similarities to 
fosfazinomycin, in that the molecule also contains an unusual phosphorohydrazate 
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linkage, however, there is no carbon-phosphorus linkage to classify this molecule as a 
phosphonic acid (79). One could speculate that the phosphorus-nitrogen bond in FR-
900137 and fosfazinomycin may be installed in a similar biosynthetic fashion and 
comparative genomics may provide insight into the genes needed for this unsolved 
transformation.  
 
Figure 1.11. Fosfazinomycin biosynthetic gene clusters from Streptomyces sp. WM6372 
and Streptomyces sp. XY332. Current proposed fosfazinomycin biosynthetic pathway 
based on currently published data.  
1.6 DIHYDROXYPROPYLPHOSPHONIC ACID – A COMMON 
INTERMEDIATE IN THE BIOSYNTHESIS OF VALINOPHOS AND 
PHOSPHONOTHRIXIN 
1.6.1 Discovery and bioactivity of the herbicide phosphonothrixin 
Phosphonothrixin was originally isolated from the fermentation broth of 
Saccharothrix sp. ST-888 in 1995 (69, 132) during a search for new compounds showing 
herbicidal activity. This new phosphonic acid showed promise as an herbicide, as the 
compound readily bleached the leaves of different gramineous and broadleaf weeds, 
killing every one of the 12 different weeds tested at a rate >50% if applied directly to the 
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leaf (132). To this day, we still do not know the mode-of-action of this herbicidal 
compound. Lange and colleagues speculated that phosphonothrixin may target 1-
deoxyxylulose 5-phosphate reductoisomerase (DXR) because of the structural similarity 
to deoxyxylulose phosphate (DXP), however phosphonothrixin was unable to inhibit 
isoprenoid biosynthesis in peppermint secretory cells, indicating that DXR is not the 
physiological target (84).  
1.6.2 Valinophos, a novel phosphonic acid discovered using genome mining 
Valinophos is a recently described phosphonate discovered through genome 
mining and was isolated from the fermentation broth of Streptomyces durhamensis 
NRRL B-3309 (59). This compound was not isolated in sufficient quantities for 
biological activity testing, however, a proposed pathway intermediate, (R)-2,3-
dihydroxypropylphosphonic acid (DHPPA), isolated in abundance from S. durhamensis 
extracts, showed inhibitory activity against Mycobacterium smegmatis (59).  
1.6.2.1 The valinophos and phosphonothrixin gene clusters share homologous genes 
The gene clusters for valinophos and phosphonothrixin were both described in 
2015, by Ju and colleagues and Lin and colleagues respectively (59, 89). Through 
examination of the pepM genomic neighborhood, the gene clusters for these two 
molecules were putatively assigned (Fig 1.12). Analysis of these gene clusters suggests 
that there would be a novel driving force for the thermodynamically unfavorable PepM 
reaction, as phosphonopyruvate decarboxylase and phosphonomethylmalate synthase 
homologs are absent from both the biosynthetic gene clusters. Lin and colleagues 
hypothesize that the two-component transketolase homolog, predicted to condense 
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pyruvate with phosphonopyruvate in a thiamine pyrophosphate-dependent reaction, 
would form an intermediate compound that can be subsequently reduced to form 
phosphonothrixin (89). Alternatively, it is possible that phosphonothrixin biosynthesis 
proceeds through a similar biosynthetic route to valinophos, as five of the biosynthetic 
genes are conserved between the two gene clusters (Fig 1.12). As the proposed 
valinophos gene cluster is missing TPP-dependent enzyme homologs, it is unlikely that 
valinophos proceeds through a similar biosynthetic scheme proposed by Lin and 
colleagues.  
1.6.2.2 Proposed biosynthesis of valinophos and phosphonothrixin 
Ju and colleagues hypothesized that the PepM reaction would be driven forward 
through the reduction of phosphonopyruvate by VlpB to form 2-hydroxy-3-
phosphonopropanoic acid (phosphonolactate) using a short-chain dehydrogenase 
homolog (59). Subsequently, phosphorylation of the carboxylate via VlpD would form 2-
hydroxy-3-oxo-3-phosphorylethylphosphonic acid. This compound can undergo two 
sequential reductions using VlpC, an N-acetyl γ-glutamyl phosphate reductase homolog, 
and VlpE, an alcohol dehydrogenase homolog, to form DHPPA (Fig 1.12). After this 
common intermediate, the valinophos and phosphonothrixin biosynthetic pathways are 
likely to diverge. It is proposed that the two remaining ATP-grasp like proteins will 
install the ester-linked N-acetyl-L-valine to form the final natural product found in S. 
durhamensis extracts (59). During phosphonothrixin biosynthesis, one could imagine that 
a TPP-dependent enzyme may catalyze the condensation of pyruvate with DHPPA to 





Figure 1.12. The gene clusters from Streptomyces durhamensis NRRL B-3309 
(valinophos) and Saccharothrix sp. ST-888 (phosphonothrixin) are shown. Homologous 
enzymes are highlighted a similar color. No step of phosphonothrixin or valinophos 
biosynthesis have been characterized in vitro or in vivo, thus the biosynthetic pathways 
described above are hypothetical.  
1.7 SUMMARY AND OUTLOOK 
 Within a ten-year study, the number of phosphonic acid natural products reported 
within the literature nearly doubled due to the use of genome mining to prioritize strains 
for phosphonate discovery (59).  Even though an immense amount of characterization 
remains to be done to characterize the bio-transformations within each gene cluster, the 
knowledge that we have gained in this process has been invaluable. Through the 
accumulation of knowledge about the interesting bio-transformations involved within 
phosphonate biosynthesis, we can now quickly identify strains containing gene clusters 
that may be of interest.  This large genome-mining study targeted only actinobacteria to 
group the number of potential phosphonic acid natural product gene clusters, thus it 
would be interesting to examine the gene cluster present in all of nature to see if different 
organisms may also contain the biosynthetic machinery to produce different 
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phosphonates than those in the actinobacteria. My thesis will describe the work done to 
characterize different phosphonic acid gene clusters that have been identified during this 
large screening campaign for novel phosphonic acids (59).  
Chapter 2 of my thesis will detail the in vitro characterization of DhpA, FzmG, 
and HpxV, the non-heme iron-dependent and α-ketoglutarate-dependent dioxygenases 
that all function on small phosphonic acid substrates. Chapter 3 of my thesis will detail 
experiments done to characterize the oxime-forming N-oxidases found in 
phosphonocystoximic acid and hydroxyphosphonocystoximic acid biosynthesis. Until 
recently, the running hypothesis in the field dictated that 2AEP was solely used by 
organisms as modifications to their membranes as phosphonolipids or phosphonoglycans. 
As I will show in Chapter 3 of my thesis, 2AEP is believed to be the substrate of the 
oxime-forming enzymes, PcxL and HpxL, involved in the biosynthesis of 
phosphonocystoximic acid (34). Our current understanding is that the 
phosphonocystoximic acids, nor hydroxynitrilaphos are incorporated as lipid 
modifications in the bacteria that produce these molecules. Finally, Chapter 4 of this 
thesis will cover the work I have done to investigate the biosynthesis of 
phosphonothrixin. Little is known about the biosynthesis of this potent herbicide, yet this 
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Chapter 2: Biochemical characterization of three TauD-family dioxygenases 
involved in phosphonate biosynthesis 
2.1 INTRODUCTION 
2.1.1 Non-heme iron and α-ketoglutarate-dependent oxygenases 
 Non-heme iron and α-ketoglutarate-dependent oxygenases are common enzymes 
found in all domains of life and are known to catalyze a variety of functions involving C-
H bond activation, including, but not limited to: hydroxylation, halogenation, 
epoxidation, epimerization, dealkylation, desaturation, cyclization, and ring opening (19, 
25, 30, 32). With the number of different types of reactions these enzymes catalyze, it is 
unsurprising that these enzymes can share little sequence identity with one another, with 
the common feature of these enzymes being a conserved 2-His-1-carboxylate facial triad 
that coordinates the ferrous iron center (8, 15). 
Natural product diversity is often influenced by the different functions carried out 
by this diverse enzyme superfamily (19, 25, 30, 32) and phosphonic acid natural products 
are no exception. One of the larger families within the non-heme iron-dependent 
dehydrogenase superfamily are members of the taurine dioxygenase (TauD) family of 
enzymes (20, 30). The founding member of the TauD-family is required for use of taurine 
degradation as a sulfur source (6). TauD catalyzes the hydroxylation of taurine at the 
alpha position, relative to the sulfonate moiety, which results in fragmentation of the 
molecule to produce sulfite and acetaldehyde (Fig 2.1) (6). Since the discovery of TauD, 
numerous family members with roles in the biosynthesis of different natural products 
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have been discovered, including multiple enzymes required for synthesis of phosphonic 
acid natural products. 
 
Figure 2.1. TauD reaction and products formed (6). 
2.1.2 Non-heme iron and α-ketoglutarate-dependent oxygenases in phosphonate 
biosynthesis 
To date, four different phosphonate biosynthetic pathways have been 
characterized that encode members of the TauD family of non-heme iron and α-
ketoglutarate-dependent oxygenases within their gene clusters that perform a 
hydroxylation reaction, Fig 2.2. FR-33289 is a hydroxylated derivative of the potent anti-
malarial natural product, FR-900098 (23). FrbJ is a non-heme iron and α-ketoglutarate-
dependent oxygenase that catalyzes the hydroxylation of FR-900098 to yield FR-33289 
(18). Fosfazinomycin is an unusual phosphonic acid natural product that contains a 
unique hydrazide linkage of a valine-arginine dipeptide to methyl 2-hydroxy-2-
phosphonoacetic acid (Me-hPnA). FzmG is a non-heme α-ketoglutarate-dependent 
oxygenase encoded within the gene cluster that performs two biosynthetic steps within 
fosfazinomycin biosynthesis (10). First, FzmG catalyzes the oxidation of 
phosphonoacetaldehyde to phosphonoacetate. Second, after methylation of 
phosphonoacetate, FzmG catalyzes the hydroxylation of phosphonoacetate-methylester 
(Me-PnA) (10). Dehydrophos is a broad-spectrum Trojan horse antimicrobial produced 
by Streptomyces luridus (2, 5). A glycine-leucine dipeptide is amide-linked to O-
methylated dehydroaminophosphonate (ΔAla(P)) (31), which is a potent inhibitor of 
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pyruvate dehydrogenase (16). This gene cluster encodes the non-heme α-ketoglutarate-
dependent oxygenase, DhpA, which has been shown to catalyze the hydroxylation of 2-
hydroxyethylphosphonic acid (2HEP) during the biosynthesis of phosphono-
dehydroalanine (2). Hydroxyphosphonocystoximic acid and hydroxynitrilaphos are two 
unusual natural products produced by Streptomyces regensis NRRL WC-3744 (3, 12). 
Hydroxyphosphonocystoximic contains a thiohydroximate moiety, while 
hydroxynitrilaphos was the first identified nitrile-containing phosphonic acid. These 
metabolites contain a hydroxyl group on the carbon α- to the phosphonate moiety, which 
was expected to be installed via the TauD homolog, HpxV. Here we provide in vitro 
biochemical evidence demonstrating the function of HpxV.  
 
Figure 2.2. Biosynthetic routes to fosfazinomycin A (Fzm), dehydrophos (Dhp), and 
hydroxyphosphonocystoximic acid (Hpx) highlighting the reactions catalyzed by the 
TauD-family and non-heme iron, α-ketoglutarate-dependent oxygenases within each 




2.1.3 DhpA, FzmG, and HpxV are evolutionarily distinct from one another 
To date, only one of the non-heme iron, α-ketoglutarate-dependent oxygenase that 
catalyzes the hydroxylation of a phosphonic acid on the carbon α- to the phosphonate 
group has been structurally characterized. However, this enzyme, PhnY, is a member of 
the phytanoyl-CoA dioxygenase sub-family (PF05721) of non-heme iron-dependent 
oxygenases (21) and is only distantly related to the enzymes within this study. No TauD-
family oxygenases that catalyze hydroxylation of phosphonic acids on the carbon α- to 
the phosphorus atom have been structurally characterized. Here, we investigate the 
differences between DhpA, FzmG, and HpxV that drive the differences in substrate 
specificity of these enzymes, which catalyze the hydroxylation of small, structurally 
similar phosphonic acid intermediates early in their respective biosynthetic pathways. 
Surprisingly, despite their ability to catalyze similar reactions, the enzymes share low 
amino acid identity for one another and are structurally divergent. This suggests that 
these enzymes have been recruited into phosphonate biosynthesis from alternative 
biosynthetic pathways multiple times throughout evolutionary history.  
2.2 RESULTS 
2.2.1 HpxV uses 2AEP as a substrate and produces (S)-1H2AEP 
Hydroxynitrilaphos and hydroxyphosphonocystoximate both contain a 
hydroxylated carbon α- to the phosphorus atom (12). The logical gene to encode a protein 
to install this hydroxyl group is the non-heme iron and α-ketoglutarate-dependent 
oxygenase homolog, hpxV, which is not present in the organism that produces the related, 
non-hydroxylated natural product phosphonocystoximate (9, 12). To determine the 
product formed by HpxV, we incubated 6x-His-tagged HpxV with 2AEP in the presence 
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of α-ketoglutarate. After incubation, one product was observed (Fig 2.3-2.4), which was 




P NMR (600 MHz) of a 12-hour HpxV enzyme reaction showing 








H two-dimensional HMBC NMR (600 MHz) of a 12-hour HpxV 





To determine the absolute stereochemistry of the product formed by HpxV, we 
performed polarimetry to determine the specific rotation of enzyme-generated 1H2AEP. 
Complete turnover of 2AEP to 1H2AEP was observed at 12 hours, determined by 
31
P 
NMR (Fig 2.3). The reaction product was purified using anion-exchange chromatography 
as previously described (7) (Fig 2.5-2.6). The specific rotation of the purified reaction 
product was determined to be [α] = + 32.9, which is consistent with reported values for 
















2.2.2 The oxygenases are substrate specific 
 A previous study has investigated the substrate specificity of FzmG and DhpA. 
Huang and colleagues showed that FzmG can hydroxylate both Me-PnA in addition to 
2HEP, while DhpA only formed product in the presence of 2HEP (10). Knowing this, we 
wished to know whether DhpA and FzmG could use 2AEP, the substrate of HpxV, and if 
HpxV could use 2HEP or Me-PnA. We analyzed the substrate specificity of the 
oxygenases two different ways: (1) by monitoring oxygen consumption of the 
oxygenases in the presence of different phosphonic acid substrates (Fig 2.7a) and (2) by 
monitoring product formation of the oxygenases via 
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Figure 2.7. Activity assays using DhpA, FzmG, and HpxV showing that these 
oxygenases are substrate-specific. (A) Oxygen-consumption by the enzymes in the 
presence of 2HEP, Me-PnA, or 2AEP. The reactions were set up as follows in PBS 
buffer: 600 μM α-ketoglutarate, 500 μM ascorbic acid, 2 mM phosphonic acid substrate, 
and 5 μM of enzyme, with the stock reconstituted in four-times the amount of ferrous 
iron. (B) Product-formation observed by the enzymes in the presence of 2HEP, Me-PnA, 
or 2AEP. The reactions were set up with 10 mM α-ketoglutarate, 1 mM ascorbic acid, 5 
mM phosphonic acid substrate, 5 μM of enzyme, and 200 μM ammonium ferrous iron 
sulfate in the reactions.  
 As shown in Fig 2.7, all three oxygenases are highly substrate specific. FzmG was 
confirmed to utilize 2HEP and Me-PnA as substrates (10) (Fig 2.8-2.9), and even though 
this enzyme can utilize four different phosphonic acids as substrates (10), FzmG was 
unable to catalyze product formation or consume oxygen in the presence of 2AEP (Fig 
2.7 and Fig 2.10). DhpA was identified to be able to use only 2HEP by monitoring the 
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P NMR analysis of the oxygenases when using 2HEPn as a substrate. 
Substrates and cofactors were added at the following concentrations in PBS buffer: 10 
mM α-ketoglutarate, 1 mM ascorbic acid, 5 mM 2HEPn, 200 μM ammonium ferrous iron 








P NMR analysis of the oxygenases when using Me-PnA as a substrate. 
Substrates and cofactors were added at the following concentrations in PBS buffer: 10 
mM α-ketoglutarate, 1 mM ascorbic acid, 5 mM Me-PnA, 200 μM ammonium ferrous 





P NMR analysis of the oxygenases when using 2AEP as a substrate. 
Substrates and cofactors were added at the following concentrations in PBS buffer: 10 
mM α-ketoglutarate, 1 mM ascorbic acid, 5 mM 2AEP, 200 μM ammonium ferrous iron 
sulfate, and 5 μM enzyme. 
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2.2.3 HpxV and DhpA catalyze hydroxylation of their phosphonic acid substrates 
with similar catalytic efficiency to FzmG 
 Oxygen consumption by HpxV or DhpA was monitored using either 2AEP or 
2HEP as substrates, respectively, to determine the kinetic parameters of the oxygenases. 
Oxygen consumption of DhpA in the presence of 2HEP fits a substrate inhibition model 
(Fig 2.11). DhpA shares almost identical kinetic parameters to FzmG when utilizing 
2HEP as a substrate (Table 2.1); however, in contrast to FzmG, DhpA shows substrate 
inhibition in the presence of millimolar levels of substrate, which is ten-fold the KM of the 
enzyme (Table 2.1) (Fig 2.11).  
 
 
Figure 2.11. Kinetic curve for DhpA using 2HEP as a substrate. The data were fit to a 
substrate inhibition model. The KM was determined to be 220 ± 30 μM. while the 
apparent kobs was observed to be 0.45 ± 0.03 s
-1
, which gives a catalytic efficiency DhpA 






). The enzyme was inhibited by substrate concentrations 





Figure 2.12. Kinetic curve for HpxV using 2-aminoethylphosphonate as a substrate. The 
data were fit to a Michaelis-Menten model. The KM was determined to be 700 ± 100 μM, 
while the apparent kobs was observed to be 0.33 ± 0.03 s
-1
, which gives a catalytic 







Oxygen consumption of HpxV in the presence of 2AEP fits a standard Michaelis-
Menten model (Fig 2.12). The KM of HpxV was determined to be approximately three-
fold higher than FzmG and DhpA for its substrate (Table 2.1). 
Table 2.1. Michaelis-Menten kinetics of the oxygenases in this study determined by 
monitoring oxygen consumption of the enzymes. The data were fit to either a Michaelis-
Menten fit (MM) or substrate inhibition model (SI). N/A indicates that substrate 
















HpxV 2AEP MM 0.33 ± 0.03 700 ± 100 0.4 x 10
3
 N/A 
DhpA 2HEP SI 0.45 ± 0.03 220 ± 30 2.0 x 10
3
 4.2 ± 0.7 
FzmG* 
2HEP MM 0.35 ± 0.02 210 ± 40 1.7 x 10
3
 N/A 
Me-PnA MM 0.27 ± 0.01 80 ± 20 3.4 x 10
3
 N/A 
The asterisk next to FzmG indicates that these data shown are previously published by 





2.2.4 The oxygenases share common ancestry with non-phosphinic acid oxygenases 
 All of the oxygenases catalyze the same reaction on similar substrates as part of 
different phosphonic acid biosynthetic pathways. Comparisons of the amino acid 
sequences of the oxygenases to one another show that they share very little similarity, 
with DhpA and FzmG sharing the highest similarity at 42% amino acid identity, while 
the similarity of all of the other proteins to one another is below 30% amino acid identity 
(Table 2.2). This suggests that the oxygenases are highly divergent from one another. To 
test this, we constructed a phylogenetic tree using homologs of the different TauD-
family, non-heme iron-dependent enzymes that are known to hydroxylate a phosphonic 
acid substrate: DhpA, FzmG, HpxV, and FrbJ. 
Table 2.2. Percent identity comparisons of the proteins in this study. The amino acid 
sequences were aligned using MAFFT (13) and the percent identity is shown through 
analysis through Geneious (14). 
  HpxV DhpA FzmG 
HpxV 100 24 25 
DhpA 24 100 25 
FzmG 25 42 100 
 
 
This tree shows that DhpA and FzmG share a common ancestor not shared by the 
other oxygenases (Fig 2.13). Within this clade, we find that there are other 
uncharacterized oxygenases that have a PEP mutase homolog within their genomic 
neighborhood, suggesting that they are involved in phosphonate biosynthesis (Fig. 2.14). 
We can predict the substrates of these enzymes based on the presence of certain genes 
within the genomic context of the biosynthetic gene cluster. Gene clusters containing an 
iron-dependent alcohol dehydrogenase homologous to DhpC will likely use 2HEP as a 
substrate. Those clusters lacking a dehydrogenase homolog, but containing a SAM-
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dependent methyltranserfase are hypothesized to use Me-PnA as a substrate. HpxV and 
other non-phosphonic acid oxygenases share a common ancestor not shared with FzmG 
and DhpA (Fig 2.13 - 2.14). The most closely related homologs are from Pseudomonas 
(Fig 2.14). 
 
Figure 2.13. Maximum-likelihood phylogeny of homologous enzymes to DhpA, FzmG, 
and HpxV. The tree shown is a snapshot of a larger phylogenetic tree shown in Figure 
2.14 to show the enzymes in this study. All highlighted branches are oxygenases located 
within 15 genes upstream or downstream of a PEP mutase homolog, indicating the likely 
involvement of these enzymes in phosphonate biosynthesis. Asterisks denote the 
enzymes used in this study: green is HpxV, purple is FzmG, and orange is DhpA. Green 
branches indicate oxygenases within an Hpx gene cluster context. Light green branches 
have an oxygenase with a 2AEP aminotransferase homolog within the genomic context. 
Orange branches indicate oxygenases within a Dhp gene cluster context. Light orange 
branches have an oxygenase with an iron-dependent dehydrogenase homolog within the 
genomic context. Purple branches indicate oxygenases within an Fzm gene cluster 
context. Light purple branches have an oxygenase with a SAM-dependent 
methyltransferase homolog within the genomic context. Blue branches indicate 
oxygenases that have no enzyme homologous to the enzymes needed to generate 2AEP, 












Figure 2.14. Full maximum-likelihood phylogeny of homologous enzymes to DhpA, 
FzmG, HpxV, and FrbJ that is showing in Fig 2.13. Highlighted branches are TauD-
homologs located within 15 genes upstream or downstream of a PEP mutase homolog. 









2.3.1 DhpA and HpxV are substrate specific, while FzmG shows substrate 
promiscuity 
 DhpA and HpxV only utilize 2HEP and 2AEP, respectively, which are 
phosphonic acids that are part of dehydrophos and hydroxyphosphonocystoximic acid 
biosynthesis. Oxygen-consumption and product formation experiments suggest that 
HpxV utilizes only 2AEP as a substrate, whereas DhpA uses 2HEP. The enzymes cannot 
use substrates that are not directly involved in the early biosynthetic steps of the 
pathways of these natural products. This may provide a biosynthetic check-point that 
helps to ensure the correct natural product is being produced. For example, during 
dehydrophos biosynthesis, hydroxylation of 2HEP is required for the downstream 
formation of L-aminoethylphosphonic acid, which is the substrate for oxidation to the 
vinyl functional group (2). Without hydroxylation of 2HEP, the incorrect natural product 
might be produced. In hydroxyphosphonocystoximic acid biosynthesis, the enzyme 
following HpxV shows substrate tolerance (9), so it is possible that non-hydroxylated 
products may be formed in vivo.  
In contrast, FzmG tolerates different substrates. Previous studies have identified 
that FzmG can perform two different steps in fosfazinomycin biosynthesis (10), 
catalyzing the oxidation of an aldehyde to a carboxylic acid and hydroxylation of the 
carbon alpha to the phosphonate moiety. Therefore, it was unsurprising to us that FzmG 
catalyzes the hydroxylation of 2HEP as well (10), considering the structural similarity 
between phosphonoacetaldehyde and 2HEP. FzmG utilizes Me-PnA with the highest 
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catalytic efficiency out of all the phosphonic acid substrates tested (10), suggesting this is 
the in vivo substrate of the enzyme.  
2.3.2 The FzmG and DhpA share a common ancestor not shared with HpxV 
suggesting that the oxygenases were recruited into phosphonate biosynthesis 
multiple times 
The phylogeny of FzmG is fully consistent with the observation that the enzyme 
catalyze the oxidation of 2HEP. DhpA and FzmG share a common ancestor not shared 
with HpxV. This clade appears to have evolved the function of oxidizing 2HEP, as most 
of the gene clusters have an iron-dependent dehydrogenase homolog that catalyzes the 
formation of 2HEP from phosphonoacetaldehyde (Fig 2.13) (26). Within this clade, there 
are a number of proteins that do not appear to be involved in phosphonate biosynthesis 
because those organisms do not contain a PEP mutase homolog within their genomes. 
Interestingly, the enzymes that appear to use 2AEP as a substrate all share a common 
ancestor not shared with FzmG or DhpA (Fig 2.13). Again, this is consistent with the 
observation that FzmG and DhpA cannot utilize 2AEP as a substrate, whereas HpxV is 
unable to use Me-PnA or 2HEP, the substrates of FzmG and DhpA, as substrates (Fig 
2.7).  Combined with the low sequence identity between these proteins (Table 2.2), it is 
unsurprising to see these enzymes appear to show different ancestry within the oxygenase 
tree.  
HpxV, DhpA, and FzmG all function early within their respective phosphonate 
biosynthetic pathways, use small, structurally similar phosphonic acid substrates, and 
catalyze the hydroxylation on the same part of each molecule. Therefore, we suspected 
that these enzymes would have a similar evolutionary lineage, with all the phosphonate-
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specific oxygenases having evolved from one common ancestor. To our surprise, we saw 
numerous non-phosphonate utilizing homologs within the same clades as the 
phosphonate-specific enzymes. The homologs of HpxV share common ancestor with 
non-phosphonic acid producing pseudomonads, as the entire sister clade next to those 
with a hydroxyphosphonocystoximic acid biosynthetic genomic context are homologous 
enzymes from Pseudomonas species. In contrast, DhpA and FzmG fall within a clade 
comprised of only actinobacteria.  
2.3.3 The phosphonate-specific TauD homologs fall within an uncharacterized sub-
group of TauD-family enzymes 
The TauD-family of dioxygenases remains largely unexplored enzyme family 
with a wide variety of potential substrates and functions. The 2601 proteins that make up 
the clade that include the phosphonate-specific oxygenases have no characterized 
relatives in the Swiss-Prot database (22). The closest characterized protein is CsiD 
(A7ZQ90.1), which is a putative gamma-butyrobetaine dioxygenase from E. coli, which 
shares 22%, 29%, and 39% amino acid identity with HpxV, DhpA, and FzmG 
respectively. This protein is not within the top BLAST retrieval for any of the oxygenases 
when a BLAST search is performed. This suggests that the phosphonate-specific proteins 
on this tree represent the first characterized protein sequences from this divergent group 
of proteins.  
2.4 SUMMARY AND OUTLOOK 
 Hydroxylation is an important part of functionalization of different natural 
products. Here, we show that phosphonate biosynthesis is no exception. There are many 
different phosphonate biosynthetic pathways that are predicted to involve the 
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hydroxylation of a small phosphonic acid substrate. Based on phylogenetic analysis, we 
can predict the substrates of these enzymes by what common ancestor is shared with the 
enzymes of interest. RODEO (29) analysis of the different gene clusters containing an 
HpxV, FzmG, or DhpA homologs suggests there multiple phosphonic acids that will 
involve the hydroxylation of 2HEP, although the final product is not dehydrophos based 
on differences within the genomic context. There is clade containing two FzmG 
homologs that contain a methyltransferase similar to FzmB (10), although the gene 
cluster does not appear to make fosfazinomycin. These two natural product gene clusters 
likely produce Me-HPnA. There are some natural product gene clusters that likely will 
form 1H2AEP as a final product based on enzyme homology to HpxV and the gene 
clusters contain a 2AEP aminotransferase homolog, although the final natural product is 
unknown. There are only six natural product gene clusters in which we cannot predict the 
substrate for the TauD-family oxygenase within the gene cluster. This suggests that based 
on genomic context, we can predict the likely substrates for most phosphonate-specific 
oxygenases.   
2.5 MATERIALS AND METHODS 
2.5.1 Protein overexpression and purification 
 Plasmids containing dhpA (4), fzmG (10), or hpxV (9)  were transformed into E. 
coli Rosetta DE3 cells. Cells were grown in Luria Broth at 37°C until the cultures 
reached optical density (OD600) 0.6-0.8. The cultures were placed on ice for 30 minutes 
and protein expression was induced upon addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Cells were shaken at 
18°C for an additional 16 hours after induction. Cells were collected via centrifugation at 
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4500 x g for 15 minutes and the cell pellets were resuspended in ice cold cell lysis buffer 
(300 mM sodium chloride, 50 mM sodium phosphate (dibasic), 10% glycerol and 20 mM 
imidazole, pH 8.0) containing 1 mg/mL lysozyme, 100 units DNase I, and 100 μg RNase 
A, and were incubated for 30 minutes at 4°C. The cells were lysed upon passage through 
a French Press cell disruptor (Thermo Electron Corporation, Waltham, MA) two times at 
1000 psi to lyse cells and the suspension was centrifuged at 17,500 x g for 30 minutes at 
4°C. The soluble fraction was mixed with 5 mL of Ni-NTA resin and incubated for 30 
minutes at 4°C and the flow through containing unbound protein was discarded. The 
resin was washed with 20 column volumes of ice cold wash buffer (300 mM sodium 
chloride, 50 mM sodium phosphate (dibasic), 10% glycerol and 50 mM imidazole, pH 
8.0) to elute loosely bound proteins. To elute proteins from the Ni-NTA resin, 15 mL of 
ice cold elution buffer (300 mM sodium chloride, 50 mM sodium phosphate (dibasic), 
10% glycerol and 250 mM imidazole, pH 8.0) was mixed with the resin and was 
incubated for 15 minutes at 4°C. The flow through containing eluted proteins were 
concentrated in 10 kDa molecular weight Amicon
®
 Ultra spin filters (EMD Millipore, 
Burlington, MA). Each protein was exchanged into protein storage buffer (300 mM 
sodium chloride, 50 mM sodium phosphate (dibasic), and 10% glycerol, pH 8.0) using a 
PD-10 desalting column (GE Healthcare Life Sciences, Marlborough, MA) following 
manufacturer instructions. Proteins were flash frozen using liquid nitrogen and stored at -
80°C until use.  
2.5.2 DhpA and HpxV kinetic assays 
 Enzyme assays were monitored using a Clark-type oxygen electrode (Hansatech 
Instruments, Norfolk, England).  The reactions were set up with the following 
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components: air saturated buffer (phosphate buffered saline (PBS): 274 mM sodium 
chloride, 8 mM sodium phosphate dibasic, 2 mM potassium chloride, and 1.4 mM 
potassium phosphate monobasic, pH 7.4), 600 μM α-ketoglutarate (buffered to pH 7.5 
with sodium hydroxide), 500 μM ascorbic acid, 25 μM – 10 mM substrate (buffered to 
pH 7.5 using sodium hydroxide), and 1 μM HpxV or 5 μM DhpA. Enzymes were 
incubated anaerobically with two equivalents of ammonium ferrous iron sulfate for 15 – 
20 minutes prior to assays on ice. DhpA was removed from the anaerobic chamber and 
kept under a nitrogen atmosphere until use in each assay. Activity of DhpA was 
consistent for upwards of 2 hours upon removal from the anaerobic chamber. HpxV was 
not as stable, which was noted by a decrease in enzyme activity within 30 minutes after 
removal of the enzyme from the anaerobic chamber, even with the enzyme being held 
under a nitrogen atmosphere. Therefore, a new aliquot of HpxV from the -80°C storage 
stocks were reconstituted anaerobically with fresh ferrous iron sulfate every 30 minutes. 
The reactions were initiated upon addition of phosphonic acid substrate.  
2.5.3 Product formation assays 
 Product formation was monitored via 
31
P NMR spectroscopy. The reactions were 
set up as follows in PBS buffer: 10 mM α-ketoglutarate (buffered to pH 7.5 with sodium 
hydroxide), 1 mM ascorbic acid,5 mM phosphonic acid substrate (buffered to pH 7.5 
using sodium hydroxide), 200 μM ammonium ferrous iron sulfate, and 5 μM enzyme. 
Reactions were allowed to proceed at room temperature for three hours. Post reaction, 
EDTA was added to the reactions to a final concentration of 9 mM to chelate the iron. 





Ultra spin filter (EMD Millipore, Burlington, MA) and product formation was 
determined using 
31
P NMR spectroscopy. 
2.5.4 Oxygen consumption assays 
 Oxygen consumption of the oxygenases in the presence either 2AEP, Me-PnA, or 
2HEP was monitored using a Clark-type oxygen electrode. The reactions were set up as 
follows in PBS buffer: 10 mM α-ketoglutarate (buffered to pH 7.5 with sodium 
hydroxide), 1 mM ascorbic acid, 5 mM phosphonic acid substrate (buffered to pH 7.5 
using sodium hydroxide), 200 μM ammonium ferrous iron sulfate, and 5 μM enzyme. 
Reactions were initiated using substrate and the rate of oxygen consumption was 
measured until completion. The first ten percent of the oxygen-consumption curve was 
measured in order to obtain steady-state kinetic data on each enzyme. Enzyme reactions 
that showed a complete cessation of oxygen consumption upon addition of substrate are 
marked with an asterisk. 
2.5.5 Stereochemistry determination of (S)-1H2AEP produced by HpxV 
(S)-1H2AEP was generated using HpxV, the 2AEP-dependent α-ketoglutarate-
dependent dioxygenase from S. regensis NRRL WC-3744. The reactions contained 50 
mM phosphate buffered saline, pH 7.4, 40 mM α-ketoglutarate, 1 mM iron sulfate, 7.5 
mM 2AEP, 4 mM L-ascrobic acid, and 200 µM HpxV. The reaction was quenched using 
5 reaction equivalents of 100% methanol. Precipitated enzyme was removed by 
centrifugation and methanol was removed under reduced pressure rotatory evaporation. 
(S)-1H2AEP was purified using weak anion exchange chromatography as previously 
described (7). Sample concentration of purified material was determined using 
31
P-NMR, 
with dimethylphosphinic acid as an internal reference standard. The optical rotation of 
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the purified product formed via this enzymatic reaction was determined using a Jasco P-
2000 digital polarimeter. A sodium lamp was used as the light source (589nm) and was 
measured through a 5 cm flint glass cell. The value obtained was compared to recorded 
literature values to determine the correct stereoisomer (27).  
2.5.6 Construction of phylogenetic trees 
The construct the oxygenase phylogenetic tree, a PSI-BLAST was performed (1) 
using DhpA (ACZ13452.1), HpxV (WP_030990672.1), FzmG (WP_053787798.1), and 
FrbJ (ABB90399.1) as the queries were retrieved on March 26, 2018. One iteration was 
run for each protein and all of the accession numbers between the query protein sequence 
and the most distantly related phosphonate homolog (FrbJ for DhpA, FzmG, and HpxV 
and FzmG for FrbJ) were collected. Escherichia coli MG 1655 TauD (Accession 
number) was used as the outgroup in this tree because it was not within the PSI-BLAST 
retrieval and it has a characterized function. Duplicate accession numbers were removed 
and the remaining 2601 amino acid sequences were aligned using MAFFT (default 
settings) (13). A maximum-likelihood phylogenetic tree was generated using FastTree 
(24). The accession numbers for each amino acid sequence was analyzed using RODEO 
(29), and if a PEP mutase homolog was found within 15 genes upstream or downstream 
of the oxygenase, these branches were highlighted on the tree, indicating the likelihood 
that this protein is involved in phosphonate biosynthesis. Green branches are HpxV 
homologs that share a phosphonocystoximic acid genomic context. Light green branches 
indicate that the phosphonate gene cluster associated with the HpxV homolog contains a 
2AEP aminotransferase homolog within the gene cluster, but is not a 
phosphonocystoximic acid biosynthetic gene cluster. Orange highlighting indicates a 
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DhpA homolog in the genomic context of the dehydrophos gene cluster. Light orange 
highlights indicate a DhpA homolog that is not in a dehydrophos biosynthetic gene 
cluster, but contains an iron-dependent dehydrogenase homolog within the gene cluster. 
Purple highlighting denotes a FzmG homolog in a fosfazinomycin genomic context, 
whereas purple highlighting indicates a FzmG homolog within a genomic context that 
does not contain an iron-dependent dehydrogenase, but does contain a homologous 
enzyme to FzmB, the SAM-dependent methyltransferase responsible for methylation of 
phosphonoacetate. Yellow highlighting of the branches indicates FrbJ homologs in the 
genomic context of FR-33289 biosynthetic genes (11). Red highlights predict a TauD-
homolog in the genomic context of fosfonochlorin biosynthesis (28). Finally, blue 
branches denote TauD-family oxygenases in a phosphonic acid biosynthetic genomic 
context with no known phosphonic acid structure known, nor contain any homologous 
enzymes to the ones listed above for other highlighting. The Interactive Tree of Life 
(ITOL) (17) was used to trim the 2601-member tree to show the clade (342 proteins) 
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Chapter 3: Biochemical characterization of a novel class of flavin-dependent, oxime-
forming N-oxidases involved in the biosynthesis of phosphonocystoximic acids1 
3.1 INTRODUCTION 
3.1.1 Oxime-containing natural products 
Oxime-containing small molecules often possess useful biological properties, 
including antibacterial (25), antifungal (20), insecticidal (5, 33), antitumor (18), 
immunosuppressive (28), and acetylcholinesterase reactivation activities (15, 46). Some 
of these bioactive oximes are natural products, with the most commonly identified being 
the glucosinolates (Fig 1). These amino acid-derived natural products, produced by plants 
of the order Capparales, contain a sulfonated oxime responsible for the distinctive flavor 
and odor of many cruciferous vegetables (17). Other natural product oximes include the 
vibralactoximes, which are biosynthetic derivatives of the lipase inhibitor vibralactone, 
produced by the fungus Boreostereum vibrans (10), the DNA methyltransferase inhibitor, 
psammaplin A, produced by the sea sponge Psammaplinaplysilla (4), and the β-lactam 
antibiotic, nocardicin A, produced by the actinobacterium Nocardia uniformis subsp. 
tsuyamanesis (25, 26) (Fig 3.1).  
                                                          
1 Most of this chapter was reprinted from Goettge, M. N., Cioni, J. P., Ju, K.-S., Pallitsch, 
K. & Metcalf, W. W. PcxL and HpxL are flavin-dependent, oxime-forming N-oxidases in 
phosphonocystoximic acid biosynthesis in Streptomyces. J. Biol. Chem. 293, 6859–6868 
(2018). This work was supported by NIH grant number P01 GM077596 B and the 
Austrian Science Fund (FWF): P27987-N28. NMR spectroscopy data collected in this 
study was done so at the Carl R. Woese Institute for Genomic Biology Core Facilities on 




Figure 3.1. Oxime-containing natural products. 
Three different enzyme families are known to produce oxime moieties: (1) 
cytochrome P450-dependent monooxygenases, (2) ferritin-like enzymes, and (3) flavin-
dependent N-monooxygenases. Glucosinolates are usually made via a pathway involving 
a cytochrome P450-dependent monooxygenase that catalyzes successive N-oxidations to 
yield an oxime-derivative of an amino acid (13, 17); however, these molecules are 
probably made via an unknown FAD-NAD(P)H-dependent oxygenase in Brassica napus 
and Brassica camestris (6, 7). In bacteria, the oxime in nocardicin A is installed by a 
cytochrome P450-dependent monooxygenase, known as NocL (25, 26), whereas a metal-
dependent N-oxygenase, AlmD, is responsible for oxime-formation in althiomycin (12). 
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Finally, the oxime in the ribosomally-synthesized peptide azolemycin is post-
translationally installed by the flavin-dependent monooxygenase, AzmF (31), while the 
oxime in caerulomycin A, is introduced using a two-component flavin-dependent 
monooxygenase, CrmH (49).  
3.1.2 Phosphonocystoximic acids 
Our lab recently identified two new phosphonate natural products with an unusual 
thiohydroximate moiety (21). These include phosphonocystoximic acid, produced by 
Streptomyces sp. NRRL S-481 and its hydroxylated congener, 
hydroxyphosphonocystoximic acid, made by a number of Streptomyces species, 
including Streptomyces regensis NRRL WC-3744, which also makes hydroxynitrilaphos 
(11). Significantly, many hydroxyphosphonocystoximate producers make small amounts 
of phosphonocystoximic acid, as well as a suite of biosynthetic intermediates that differ 
solely by hydroxylation at the carbon alpha to the phosphorus atom, suggesting similar 
molecular machinery is used to produce both natural products (21). This idea is strongly 
supported by analysis of the biosynthetic genes clusters associated with production of 
these oxime-containing natural products.  
Eighteen genes are shared between the clusters responsible for synthesis of 
phosphonocystoximate (the pcx gene cluster) and hydroxyphosphonocystoximate (the 
hpx gene cluster), based on significant amino acid identity between the encoded proteins 
(Fig 3.2, Table 3.1). The first nine genes (hpxA-hpxI and pcxA-pcxI) in both clusters are 
highly homologous and found in the same order. Nine additional genes are also shared 
between the two clusters, with their organization being conserved for the most part 
(pcxK-pcxU and hpxK-hpxU). Thus, it seems likely that most of the biosynthetic steps 
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required for synthesis of the two congeners are similar. However, the gene clusters also 
show significant differences. Key among these is a gene encoding a putative 2-
oxoglutarate-dependent dioxygenase designated HpxV, found solely in S. regensis. Based 
on the presence of this gene and the observed metabolic intermediates produced by the 
two strains, a scheme for biosynthesis of phosphonocystoximate and 
hydroxyphosphonocystoximate biosynthesis was proposed (Fig 3.2) (21). The proposed 
pathways diverge at an early step, with hydroxylation of 2-aminoethylphosphonic acid 
(2AEPn) by HpxV yielding 1-hydroxy-2AEPn (1H2AEPn) solely in S. regensis. 
Consistent with this model, we recently showed that purified HpxV catalyzes this 
reaction, generating the S-enantiomer of 1H2AEPn (Chapter 2). The mechanism of 
oxime formation in the two pathways, however, remains a mystery because homologs of 
known oxime-forming enzymes are not found in either biosynthetic gene cluster. 
Nevertheless, putative NAD(P)H-dependent and flavin-dependent oxygenases produced 
by the pcxL and hpxL genes, in Streptomyces sp. NRRL S-481 and S. regensis, 
respectively, were suggested as possible candidates for this enzymatic activity (21).  
Here we present in vitro biochemical evidence that supports this proposal. The 
data reveal PcxL and HpxL as the founding members of a novel family of oxime-forming 
enzymes required for production of the hydroxylated and non-hydroxylated forms of 







Table 3.1. Comparison of the phosphonocystoximate (Pcx) and 
hydroxyphosphonocystoximate (Hpx) gene clusters. Genes with the same corresponding 
fourth letter of the gene are homologous to one another. Percent amino acid identity 
between the proteins is given based on BLAST. NP = not present within the gene cluster 

















%Identity Putative Function / Description Pfam 
pcxA 404 WP_030230281.1 hpxA 409 WP_030990657.1 57% 
Helix-turn-helix domain transcriptional 
regulator 
PF13560 
pcxB 60 WP_030230290.1 hpxB 201 WP_030646389.1  Hypothetical protein 
No 
Match 
pcxC 412 WP_051704820.1 hpxC 414 WP_030990660.1 64% ATP-grasp domain containing protein PF13535 
pcxD 413 WP_051704821.1 hpxD 415 WP_048910652.1 70% ATP-grasp domain containing protein PF13535 
pcxE 484 WP_030230301.1 hpxE 456 WP_030990665.1 58% 
Condensation domain containing 
protein 
PF00668 
pcxF 426 WP_051704822.1 hpxF 422 WP_048910653.1 76% Biotin carboxylase / ATP-grasp domain PF13535 
pcxG 418 WP_030230306.1 hpxG 419 WP_030990668.1 70% 
Major facilitator superfamily 
transporter 
PF07690 
pcxH 434 WP_030230310.1 hpxH 447 WP_030646400.1 63% Peptidase PF01523 
pcxI 451 WP_051704823.1 hpxI 447 WP_048910654.1 77% Peptidase PF01523 
pcxJ 213 WP_030230320.1 NP N/A N/A N/A Pyridoxamine 5'-phosphate oxidase PF10590 








pcxM 363 WP_037834389.1 hpxM 375 WP_030990679.1 66% Aminotransferase class-V PF00266 
pcxN 307 WP_030230335.1 hpxN 290 WP_030990678.1 55% Fosfomycin resistance kinase FomA PF00696 
pcxO 215 WP_030230340.1 NP N/A N/A N/A Thymidylate kinase PF02223 
pcxP 90 WP_030230342.1 NP N/A N/A N/A Phosphopantetheine-binding protein PF00550 
pcxQ 371 WP_037834390.1 hpxQ 395 WP_030990677.1 66% Uncharacterized nucleotidyltransferase PF14907 
pcxR 549 WP_030230346.1 hpxR 563 WP_030990676.1 58% 
Non-ribosomal peptide synthetase 
adenylation domain 
PF00501 








pcxU 286 WP_030230355.1 hpxU 286 WP_030646403.1 72% Phosphoenolpyruvate phosphomutase PF13714 
NP N/A N/A hpxV 322 WP_030990672.1 N/A TauD taurine catabolism dioxygenase PF02668 




NP N/A N/A hpxW2 182 WP_030646420.1 N/A 
Phosphonopyruvate decarboxylase beta 
subunit 
PF02775 
NP N/A N/A hpxX 86 WP_030990685.1 N/A Acyl carrier protein PF00550 
NP N/A N/A hxpY 337 WP_030990687.1 N/A 
FomB family phosphonate 
monophosphate kinase 
PF13481 
NP N/A N/A hpxZ 284 WP_030646426.1 N/A EamA-like transporter family protein PF00892 
orf1 316 WP_037834300.1 NP N/A N/A N/A 3-phosphoglycerate dehydrogenase PF02826 
orf2 367 WP_051704838.1 NP N/A N/A N/A L-iditol 2-dehydrogenase PF08240 




orf4 418 WP_051704825.1 NP N/A N/A N/A Phosphoglycerate kinase PF00162 
orf5 373 WP_030230380.1 NP N/A N/A N/A 1,3-propanediol dehydrogenase PF00465 






Figure 3.2. Top: The putative biosynthetic gene clusters for phosphonocystoximate and 
hydroxyphosphonocystoximate, found in Streptomyces sp. NRRL S-481 and 
Streptomyces regensis NRRL WC-3744, respectively. Putative gene functions are shown 
in Table 3.1. Bottom: The proposed biosynthetic route of oxime formation in 
phosphonocystoximates. HpxV is a 2-oxoglutarate- and ferrous iron-dependent 2AEPn 
dioxygenase that converts 2AEPn to (S)-1H2AEPn. PcxL and HpxL are FAD- and 
NADPH-dependent amine oxidases that catalyze 2AEPn or 1H2AEPn oxidation to yield 
2-hydroxyiminoethylphosphonic acid (1) or 1-hydroxy-2-hydroxyiminoethylphosphonic 
acid (3), respectively. Multiple steps are required to convert these oxime-containing 





3.2 RESULTS AND DISCUSSION 
3.2.1 Bioinformatic analysis suggest HpxL and PcxL are novel oxime-forming amine 
oxygenases 
Several lines of bioinformatics evidence suggest that the PcxL and HpxL proteins 
are responsible for installation of the oxime moiety in the phosphonocystoximic acids 
produced by Streptomyces sp. S-481 and S. regensis. First, conserved FAD- and NAD(P)-
binding domains are observed in both proteins, consistent with a role in redox chemistry. 
Second, both have structural similarity to the N-terminal domain of L-ornithine N-
hydroxylase from Pseudomonas (PDB entry 3S5W) and Kutzneria (PDB entry 4TLX) 
based on the protein-fold recognition algorithm, Phyre2(24). Taken together, these data 
suggest that PcxL and HpxL may catalyze FAD- and NAD(P)-dependent amine 
oxidation. Additional support for the proposed amine oxidase function is provided by 
their weak similarity (~35% identity) to FAD-NAD(P)H-dependent enzymes involved in 
the biosynthetic pathways of cremeomycin (42) and fosfazinomycin (19) (Table 1). These 
enzymes oxidize the primary amine of aspartic acid to form nitrosuccinic acid, which is 
believed to serve as the substrate for downstream N-N bond formation (42). Finally, the 
existence of the characterized oxime-forming FAD- and NAD(P)H-dependent amine 
monooxygenases in the biosynthetic pathways of azolemycin (AzmF) (31) and 
caerulomycin A (CrmH) (49) is also consistent with the proposed amine oxidase function 
for PcxL and HpxL. However, it should be stressed that AzmF and CrmH are not related 
to PcxL and HpxL based on comparison of their primary amino acid sequences (Table 
3.2). Moreover, these proteins are significantly smaller than PcxL and HpxL (389/407 
amino acids versus 742/750 amino acids). Similarly, the human liver flavin-containing 
82 
 
monooxygenases FMO1 (NCBI accession number NP_001269621.1) and FMO3 (NCBI 
accession number NP_008825.4), which oxidize phenethylamine to the oxime (30), show 
no similarity to HpxL and PcxL. Thus, if PcxL and HpxL are indeed FAD-NAD(P)H-
dependent enzymes that catalyze oxime formation, they belong to a novel protein family. 
Table 3.2. Known, characterized N-oxidases and their homology to HpxL, which is 
encoded by the hydroxyphosphonocystoximic gene cluster. PcxL is found in the 
homologous phosphonocystoximic biosynthetic gene cluster. FzmM and CreE catalyze 
the N-oxidation of aspartic acid to nitrosuccinic acid during fosfazinomycin (19) and 
cremeomycin (42) biosynthesis, respectively. AzmF (31) and CrmH (49) are 
characterized flavin-dependent N-oxidases that catalyze oxime formation in azolemycin 
and caerulomycin biosynthesis. ClmM is the predicted FAD- NAD(P)H-dependent N-
oxidase of collismycin biosynthesis (16), while AlmD is the metal-dependent N-oxidase 
involved in oxime formation of alithomycin biosynthesis (12). Note that only FzmM and 












































Cremeomycin 35% 3E-29 666 
3.2.2 HpxL and PcxL catalyze NADPH oxidation in the presence of FAD and 
2AEPn  
To examine the biochemical properties of PcxL and HpxL, 6xHis-affinity-tagged 
alleles were overexpressed in E. coli. Recombinant proteins were then purified and 
assayed for their ability to oxidize nicotinamide cofactors in the presence of 2AEPn, FAD 
or FMN (Table 3.3). Both enzymes catalyze oxidation of NADPH and NADH at a 
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significant rate in the absence of additional substrates. Oxidation of reduced 
nicotinamides is stimulated by the addition of FAD, but not by addition of FMN, 
suggesting that the former is the preferred cofactor. It should be noted that the as-purified 
enzymes contain bound FAD, as indicated by the bright yellow coloration of preparations 
(Fig 3.3A). Additionally, we conclude that the flavin cofactor bound to the N-oxidases is 
FAD because of the presence of FAD in the protein preparations as determined by 
LC/ESI mass spectrometry (Fig 3.3B) and the maximum absorbance of the proteins being 
consistent with the presence of FAD (Fig 3.3C-E). We believe the presence of FAD 
bound to the proteins upon purification accounts for the basal activity seen in the absence 
of added FAD. Significantly, oxidation of NADPH, but not NADH, is substantially 
increased upon addition of 2AEPn, with the highest rates being observed for the 
combination of NADPH, FAD and 2AEPn. Thus, activity in the absence of 2AEPn is 
likely due to an uncoupled, oxygen-dependent reaction, which is common for flavin-
dependent enzymes (45). Additionally, when this reaction is run in the absence of 
oxygen, there is no oxidation of NADPH by PcxL, in either the presence or absence of 











Table 3.3. Oxidation of nicotinamide cofactors by HpxL and PcxL. The apparent rate in 
the presence/absence of different flavin cofactors and 2AEPn is shown. 2AEPn* = rate in 
the presence of 2AEPn after subtraction of the uncoupled rate (i.e. before addition of 
2AEPn). 2AEPn was used at a concentration of 5 mM, while FAD and FMN were used at 
50 μM, and NADPH or NADH were used at 300 μM. Each experiment was completed in 
triplicate. 





Cofactor(s) Substrate HpxL PcxL 
NADPH 
none 2.7 ± 0.4 14.4 ± 0.7 
2AEPn 7.2 ± 0.6 232 ± 8 
NADPH/FAD 
none 12.5 ± 0.1 21 ± 1 
2AEPn 23.2 ± 0.7 310 ± 20 
2AEPn* 10.7 ± 0.6 290 ± 20 
NADPH/FMN 
none 5.2 ± 0.5 14.3 ± 0.7 
2AEPn 10.0 ± 0.2 210 ± 20 
2AEPn* 4.8 ± 0.7 200 ± 20 
NADH 
none 5.5 ± 0.1 24 ± 1 
2AEPn 1.7 ± 0.2 29 ± 2 
NADH/FAD 
none 14 ± 2 85 ± 5 
2AEPn 15.0 ± 0.7 83 ± 5 
2AEPn* 0.1 ± 0.1 0 ± 3 
NADH/FMN 
none 5.9 ± 0.3 26.6 ± 0.2 
2AEPn 7.0 ± 0.4 27 ± 4 







Figure 3.3. Characterization of HpxL and PcxL as FAD-dependent enzymes. (A) The top 
photograph is of purified 6xHis tagged N-oxidases after purification. The bottom 
photograph shows the enzyme after incubation with NADPH. (B-E) Low resolution mass 
spectrometry of the flavin isolated from (B) HpxL (37.1 μM) and (C) PcxL (30.9 μM). 
(D) FAD standards and (E) FMN standards were used at a concentration of 50 μM. (F) 
HpxL absorption spectra of purified flavin (dark blue squares) or HpxL before (blue 
circles) and after (light blue triangles) incubation with NADPH. Inset shows the 
maximum absorption of HpxL at 363 nm and 452 nm. Purified flavin from washed HpxL 
shows absorption maxima at 374 nm and 450 nm. (G) PcxL absorption spectra of purified 
flavin (dark purple squares) or the protein before (purple circles) and after (light purple 
triangles) incubation with NADPH. Inset shows the maximum absorption of PcxL at 383 
nm and 448 nm. Purified flavin from washed PcxL shows absorption maxima at 377 nm 
and 450 nm. (H) Control reactions showing FAD absorption (red circles), NADPH 
absorption (dark red squares), and a mixture of pure FAD and NADPH (pink triangles). 
The inset shows the absorption maxima of FAD at 377 nm and 450 nm.  The elevated 
baseline in the spectra shown in (F) and (G) are likely due to light scattering from small 
amounts of protein precipitation of HpxL and PcxL, as baseline elevation is not observed 
with the purified flavin that was washed from the proteins. We have observed that HpxL 





3.2.3 HpxL and PcxL oxidize 2AEPn to 2-hydroxyiminoethylphosphonic acid and 2-
nitroethylphosphonic acid  
A series of NMR experiments were conducted to establish the products of PcxL- 
and HpxL-catalyzed 2AEPn oxidation. Based on 
31
P NMR spectroscopy, both enzymes 
form three phosphorus-containing products after prolonged incubation with NADPH, 
FAD and 2AEPn (Fig 3.4A and Fig 3.4B). Analysis of these molecules using 2-
dimensional proton-phosphorus coupled HMBC NMR spectroscopy allowed assignment 
of the major peak as a mixture of the (E)- and (Z)-isomers of 2-
hydroxyiminoethylphosphonic acid (1), with smaller amounts of 2-nitroethylphosphonic 
acid (2) (Fig 3.5 and Fig 3.6). Accordingly, aldoxime protons display a characteristic 
proton NMR spectroscopy chemical shift that will be between 6.5 and 8.0 ppm (35). A 
single proton associated with each of the products, which we assign as (E)-1 and (Z)-1 at 
6.82 ppm and 7.37 ppm, respectively. This assignment is supported by a recent report of 
the total synthesis of the phosphonocystoximic acids, which involved the synthesis of 
ethyl protected aldoximes as intermediates. The aldoxime protons for the protected (E)-
isomer had a chemical shift of 6.82 ppm, while the aldoxime proton associated with the 
protected (Z)-isomer has a chemical shift of 7.41 ppm (34). Our assignment of the third 
product as 2 is based on the observation of phosphorus correlated protons at 2.03 ppm 
and 4.48 ppm, which is consistent with literature values of synthetically-produced 2-
nitroethylphosphonic acid (3). While both enzymes form a mixture of (E)- and (Z)-
isomers when using 2AEPn as substrate, HpxL preferentially forms (E)-1 (Fig 3.5), while 






P NMR-analysis of N-oxidase activity in the presence of 2AEPn or (S)-
1H2AEPn. (A) HpxL and PcxL form three major products in vitro when incubated for 16 
hours with NADPH, FAD and 2AEPn as the substrate, whereas no product formation is 
observed in the absence of enzyme. (B) These products have been assigned as the (E)- 
and (Z)-isomers of 2-iminoethylphosphonic acid (1) and 2-nitroethylphosphonic acid (2) 
based on the 1H-31P HMBC analysis (Fig. S2 and S3). Note that the (E)- and (Z)-
isomers of 1 have identical 31P chemical shifts and thus display only a single peak in the 
1D-31P spectrum shown in panel A. (C) HpxL and PcxL both generate two products in 
vitro using (S)-1H2AEPn as the substrate. (D) These products were assigned as (Z)-1-
hydroxy-2-hydroxyiminoethylphosphonic acid (3) and 1-hydroxy-2-nitroethylphosphonic 
acid (4) based on the 1H-31P HMBC analysis (Fig. S4 and S5). Chemical mixing 
experiments with the control reaction was performed to confirm that substrate had been 
completely consumed. Substrates and cofactors were added at the following 
concentrations: 100 μM FAD, 500 μM NADPH, 3 mM 2AEPn or HpxV-generated (S)-








Figure 3.5. HMBC NMR analysis of HpxL incubated in the presence of FAD, NADPH, 




P HMBC spectrum of the HpxL reaction with 2AEPn 
as the substrate showing all phosphorus-containing molecules in the reaction. (B) 




P spectrum with key proton-phosphorus correlations labeled 
({
1
H chemical shift, 
31





correlations with the 
1
H chemical shifts displayed in orange and 
31
P chemical shift in 
green. 2AEPn, (E)- and (Z)-1, and 2 are shown. Substrates and cofactors were added at 
the following concentrations: 100 μM FAD, 500 μM NADPH, 3 mM 2AEPn, and 25 μM 










Figure 3.6. HMBC NMR analysis of PcxL incubated in the presence of FAD, NADPH, 




P HMBC NMR spectra of the PcxL reaction with 
2AEPn as the substrate showing all phosphorus-containing molecules in the reaction. (B) 




P spectrum with key proton-phosphorus correlations labeled 
({
1
H chemical shift, 
31





correlations with the 
1
H chemical shifts displayed in orange and 
31
P chemical shift in 
green. 2AEPn, (E)- and (Z)-1 and 2 are shown. Substrates and cofactors were added at the 
following concentrations: 100 μM FAD, 500 μM NADPH, 3 mM 2AEPn, and 25 μM 
PcxL. 25 mM phosphite and 10 μM PTDH17x were also added as a cofactor regenerating 
system.     
We performed an identical experiment using 1H2AEPn as substrate to determine 
the products that would be formed by the enzymes. PcxL and HpxL catalyze oxidation of 
the amine moiety in (S)-1H2AEPn as a substrate (Fig 3.4C and Fig 3.4D).  In contrast to 
the products obtained with 2AEPn, the enzymes form only the (Z)-isomer of 1-hydroxy-
2-hydroxyiminoethylphosphonic acid (3) when using (S)-1H2AEPn as the substrate. This 
is evident by the presence of only one set of protons correlating with the phosphorus 
atom with chemical shifts of 4.15 ppm and 7.44 ppm (Fig 3.7 and Fig 3.8). The enzymes 
also form smaller amounts of 1-hydroxy-2-nitroethylphosphonic acid (4) (Fig 3.7 and Fig 






Figure 3.7. HMBC NMR analysis of HpxL incubated in the presence of FAD, NADPH, 




P HMBC NMR spectra of the HpxL reaction 
with (S)-1H2AEPn as the substrate showing all phosphorus-containing molecules in the 




P spectrum with key proton-phosphorus 
correlations labeled ({
1
H chemical shift, 
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P correlations with the 
1
H chemical shifts displayed in orange and 
31
P 
chemical shift in green. 1H2AEPn, (E)- and (Z)-3 and 4 are shown. Substrates and 
cofactors were added at the following concentrations: 100 μM FAD, 500 μM NADPH, 3 
mM (S)-1H2AEPn, and 25 μM HpxL. 25 mM phosphite and 10 μM PTDH17x were also 









Figure 3.8. PcxL was incubated in the presence of FAD, NADPH, and (S)-1H2AEPn for 




P HMBC NMR spectra of the HpxL reaction with (S)-1H2AEPn as 
the substrate showing all phosphorus-containing molecules in the reaction. (B) Magnified 
















H chemical shifts displayed in orange and 
31
P chemical shift in green. (S)-
1H2AEPn, (E)- and (Z)-3 and 4 are shown. Substrates and cofactors were added at the 
following concentrations: 100 μM FAD, 500 μM NADPH, 3 mM (S)-1H2AEPn, and 25 
μM PcxL. 25 mM phosphite and 10 μM PTDH17x were also as a cofactor regenerating 
system.     
To determine the molar ratio of substrates consumed to cofactor used, we 
determined the stoichiometry of the reaction by monitoring substrate (2AEPn and 
oxygen) and cofactor (NADPH) consumption during short incubations. We observed that 
the molar ratio of oxygen to NADPH was approximately 1:1 for both enzymes; however, 
the molar ratio of NADPH to 2AEPn consumption was much higher: 2.5:1 
(NADPH/2AEPn) for PcxL and 4.0:1 for HpxL (Table 3.4). This yields an overall 
reaction stoichiometry of 2AEPn to NADPH to oxygen consumption of 1/2.5/2.7 for 
PcxL and 1/4.0/3.8 for HpxL. Significantly, 2-nitroethylphosphonic acid was not 
observed during the short incubations used in these experiments (data not shown). Thus, 
the presence of this product in longer incubations is probably due to overoxidation of the 




Table 3.4. Stoichiometry of the PcxL- and HpxL-catalyzed reactions. Oxygen and 
NADPH consumption were measured in five-minute reactions using a Clark-type 
electrode and UV/Vis spectrophotometry, respectively, to determine the O2/NADPH 
ratio. A separate, three-hour reaction was used to obtain the NADPH/2AEPn ratio with 
31
P NMR being used to monitor both substrates. Each experiment was performed in 
triplicate.  
3.2.4 HpxL and PcxL both preferentially oxidize 1H2AEPn over 2AEPn, but with 
different stereochemical preferences 
To determine the substrate preference of the N-oxidases in vitro, we performed 
initial rate kinetics on PcxL and HpxL using 2AEPn and the (R)- and (S)-enantiomers of 
1H2AEPn as substrates (Table 3.5, Fig 3.9). Although both enzymes are capable of using 
all of these substrates, they manifest significantly different substrate preferences. PcxL 
shows the highest rate with 2AEPn as substrate, but shows a greater affinity for (R)-
1H2AEPn. Thus, the catalytic efficiency of PcxL is similar for these two substrates. In 
contrast, (S)-1H2AEPn is a relatively poor substrate for PcxL, while HpxL turns over (S)-
1H2AEPn and 2AEPn at similar rates, but has a 10-fold higher affinity for the former. 
Thus, (S)-1H2AEPn, which is predicted to be the in vivo substrate, is the preferred 
substrate for this enzyme. (R)-1H2AEPn is a relatively poor HpxL substrate and actually 
inhibits the enzyme at higher concentrations (Fig 3.9F). 
Substra
te 
























PcxL 966 ± 0.4 1040 ± 2 1 : 1.1 1970 ± 3 810 ± 30 2.5 : 1 
1 : 2.5 : 
2.7 
HpxL 163 ± 1 156 ± 2 1.1 : 1 1420 ± 30 350 ± 50 4.0 : 1 





Figure 3.9. Kinetic curves for PcxL and HpxL in the presence of different substrates. The 
kinetic constant values are shown below in Table 3.5. (A) PcxL and (B) HpxL with 
2AEPn as the substrate fit a standard Michaelis-Menten curve. (C). PcxL and (D) HpxL 
with (S)-1H2AEPn fit to the standard Michaelis-Menten equation. (E) PcxL with (R)-
1H2AEPn fit to the standard Michaelis-Menten equation and (F) HpxL with (R)-
1H2AEPn fit for substrate inhibition.  
 
Table 3.5. Initial rate kinetics for HpxL and PcxL. Rates were determined by monitoring 
NADPH consumption via UV-Vis spectrophotometer. Vmax, Km, and Ki were determined 
by fitting the data with either Michaelis-Menten (MM) or substrate inhibition (SI) 
models. Only best fit is shown. Reaction components included: 50 mM sodium phosphate 
buffer, pH 7.8, 300 µM NADPH, 50 µM FAD, substrate ranging from 62.5 µM to 150 
mM, and enzyme concentrations of 1 µM or 5 µM for PcxL and 5 µM or 10 µM for 
HpxL. The substrates used were pure 2AEPn, synthetic (R)-1H2AEPn, or synthetic (S)-




















2AEPn MM 1.22 ± 0.02 3.3 ± 0.5 370 n/a 
(R)-1H2AEPn MM 0.39 ± 0.01 0.48 ± 0.02 810 n/a 





4.3 ± 0.8 7.4 n/a 








3.2.5 HpxL and PcxL are members of a large family of putative N-oxidases that is 
common to phosphonate biosynthetic pathways 
The low similarity of HpxL and PcxL to other known N-oxidases suggests that 
they are members of larger protein family (Table 3.2). Indeed, BLAST searches of 
GenBank retrieve thousands of hits using HpxL and PcxL as query sequences (data not 
shown). Phylogenetic analysis of the top 500 HpxL homologs reveals numerous discrete 
clades within the family. To provide clues as to the function of the proteins within this 
family, we examined the genomic context surrounding these homologs using the 
bioinformatics tool Rodeo, which retrieves adjacent genes and assigns putative functions 
based on PFAM membership (44). Significantly, almost all genes encoding proteins 
within the HpxL and PcxL clade fall within gene clusters devoted to the synthesis of 
phosphonic acids based on co-localization with genes encoding phosphoenolpyruvate 
mutase (PepM), which encodes the first step in most phosphonate biosynthetic pathways 
(Fig 3.10A) (21, 32, 48). As described above, the known N-oxidases FzmM and CreE are 
bona fide members of this protein family; however, they are only distantly related to 
HpxL and PcxL and do not fall within the top 500 homologs shown in Fig 3.10A. Indeed, 
the BLAST search results using HpxL as the query must be extended to include the top 
5000 hits before FzmM and CreE are included. 
We performed a similar analysis using previously identified phosphonate 
biosynthetic gene clusters as the starting point (21). 23% of the phosphonate gene cluster 
families contain a HpxL homolog, with only three families having characterized 
products: the phosphonocystoximic acids, hydroxyphosphonocystoximic acids, and 
fosfazinomycins. Thus, at least 15 novel, uncharacterized phosphonic acid natural 
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product biosynthetic pathways encode a HpxL homolog. Based on the similarity of these 
enzymes within the N-oxidase tree, we can predict that these novel 15 phosphonic acids 
will likely involve the oxidation of 2AEPn or 1H2AEPn to form an oxime-containing 
natural product (Fig 3.10B). 
 
Figure 3.10. Cladograms showing the phylogenetic distribution of putative N-oxidases 
related to HpxL and PcxL. (A) Phylogeny of the 500 closest HpxL homologs. hpxL-
containing gene clusters that also contain pepM are highlighted in orange. (B) Phylogeny 
of actinobacterial PepM sequences. pepM-containing gene clusters that contain an HpxL 
homolog are highlighted in orange. HpxL is denoted with a blue asterisk, PcxL is denoted 
with a purple asterisk, and FzmM is denoted with a pink asterisk. Gene clusters were 
arbitrarily defined to include the 15 genes upstream or downstream of the N-oxidase.  
3.3 DISCUSSION 
3.3.1 PcxL and HpxL are 2AEPn and 1H2AEPn amine-oxygenases 
The data presented here show that PcxL and HpxL are novel FAD- and NADPH-
dependent oxime-forming amine oxygenases that utilize amine-containing phosphonate 
substrates. Although these enzymes were shown to oxidize several small amino 
phosphonates, the substrate preferences of the two enzymes support the proposed 
96 
 
biosynthetic pathways shown in Fig 3.2. Accordingly, we expected that the substrate 
preference of the N-oxidases would be influenced by the presence of the proposed 2AEPn 
dioxygenase, HpxV, in the gene cluster of S. regensis NRRL WC-3744 (Fig 3.2, Table 
3.1), with HpxL having a preference for (S)-1H2AEPn and PcxL having a preference for 
2AEPn (Ju, 2015). The finding that the catalytic efficiency of HpxL is 10-fold higher for 
(S)-1H2AEPn than the other substrates tested is fully consistent with this model. Our 
conclusions regarding PcxL are less certain, because the enzyme displays a similar 
catalytic efficiency with both 2AEPn and (R)-1H2AEPn. Nevertheless, it is very likely 
that 2AEPn is the natural substrate given the absence of known genes to produce 
hydroxylated phosphonate substrates in Streptomyces sp. NRRL S-481.  
3.3.2 The stoichiometry of the reaction suggests over-oxidation of substrate during 
formation of the aldoxime 
Based on the finding that NADPH and O2 are always consumed in a 1:1 ratio by 
PcxL and HpxL (Table 3.4), oxime formation should require two separate hydroxylation 
steps, each consuming one molar equivalent of NADPH and one molar equivalent of 
oxygen. Each step would also produce one molar equivalent of H2O by reduction of O2 
with NADPH. We predict that this reaction would proceed through hydroxyamino- and 
dihydroxyamino- intermediates, with subsequent loss of water producing a nitroso 
intermediate, which would tautomerize to afford the final aldoxime product observed in 
our reactions (Fig 3.11).  An infrequent, third NADPH- and O2-dependent hydroxylation 
of the dihydroxyamino-, nitroso- intermediates, or the oxime products would then afford 
small amounts of the nitro-derivatives seen in our data (Fig 3.4 - Fig 3.8). The fact that 
we see substantially higher levels of O2 consumption, relative to aldoxime formation, is 
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consistent with this idea, as is the observation of NADPH oxidation in the absence of 
phosphonate substrates (i.e. the uncoupled reaction). We expect that the latter would 
produce hydrogen peroxide, although this was not directly tested. 
 
Figure 3.11. Proposed stepwise oxidation of 2AEPn to yield 1 or 2 that may explain the 
1:2.5 substrate:NADPH ratio observed for oxime formation in vitro. We propose that 
each N-oxidation would require one molar equivalent of NADPH and molecular oxygen. 
This would require two N-oxidations and a dehydration to yield 2-nitrosoethylphosphonic 
acid, which could tautomerize to form 2-hydroxyiminoethylphosphonic acid. An enzyme-
catalyzed overoxidation of either 2-nitrosoethylphosphonic acid or 2-
hydroxyiminoethylphosphonic acid could potentially yield 2-nitroethylphosphonic acid 
(shown with grey arrows).  Compounds shown in purple are all products observed in the 
reactions catalyzed by HpxL and PcxL using 2AEPn as the substrate (Fig 3.4).  
3.3.3 PcxL and HpxL are new members of a class of flavin-dependent amine 
oxidases common in nature 
Sequence analysis shows that HpxL and PcxL are members of a very large protein 
family that is widely distributed in bacteria. Only four members of this family have been 
biochemically characterized, including HpxL, PcxL and the distantly related enzymes, 
FzmM and CreE. While the former oxidize amino phosphonates to aldoximes (and small 
amounts of nitro derivatives), the latter oxidize aspartate to nitrosuccinic acid (19, 42). 
Given the phylogenetic distance between these distant homologs, it seems reasonable to 
assume that most members of the family are amine oxidases. Interestingly, members of 
this presumptive amine oxidase family are common in actinobacterial phosphonate 
biosynthetic gene clusters, with nearly one quarter of those examined containing a 
homolog. These enzymes are widely distributed on the PepM maximum-likelihood tree, 
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suggesting HpxL and PcxL homologs were recruited into phosphonic acid biosynthetic 
gene clusters multiple times: however, all of these homologs are closely related, falling 
into the same clade within the amine oxidase tree (Fig 3.10A). Moreover, each of the 
gene clusters containing these homologs also contain the biosynthetic machinery needed 
to make 2AEPn or 1H2AEPn. Taken together, these data suggest that numerous 
phosphonate biosynthetic pathways include 2-hydroxyiminoethylphosphonic acid or 1-
hydroxy-2-hydroxyiminoethylphosphonic acid as early intermediates (see Fig 3.4). Thus, 
although the phosphonocystoximates are the only known oxime-containing phosphonate 
natural products, it seems certain that numerous additional examples await discovery.  
3.4 SUMMARY AND OUTLOOK 
 Phosphonocystoximic acid and hydroxynitrilaphos are two natural products with 
interesting functional groups on these molecules. With the discovery of the oxime-
forming enzymes, one step of the biosynthesis of these molecules has been elucidated. 
This is only a small fraction of the genes predicted to be involved in the biosynthesis of 
the phosphonocystoximic acids (21). In addition, there are many more unanswered 
questions regarding HpxL and PcxL. Here I will outline my thoughts regarding the future 
of phosphonocystoximate biosynthesis. 
PcxL and HpxL are proteins that catalyze the formation of oxime-containing 
phosphonic acids and members of a novel group of amine-oxidases. These proteins share 
little homology to known amine-oxidases outside of phosphonate biosynthesis, with the 
closest characterized homologs using aspartic acid as the substrate (19, 42). These 
proteins are substantially longer than other characterized amine-oxidases, yet the 
conserved NADPH and FAD-binding domains appear to be conserved in the N-terminal 
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domain of the protein. When performing a BLAST search (2) on the C-terminal domain 
of these proteins, no proteins with characterized or predicted functions are returned in the 
search. Therefore, we are unsure whether the C-terminal domain of this protein is 
required for the oxime-forming function of this protein. Truncation mutants of this 
protein lacking the C-terminal domain would suggest whether this domain is necessary 
for function. 
PcxL and HpxL homologs appear to be widely distributed in phosphonate 
biosynthesis (Fig 3.10).  Looking within the genomic neighborhood of these phosphonate 
biosynthetic gene clusters, most of these clusters contain a homologous gene to the 
2AEPn aminotransferase (data not shown) responsible for formation of 2AEPn from 
phosphonoacetaldehyde (8, 14, 27, 29). This suggests the substrate of these enzyme may 
be 2AEPn, although there is a possibility that these enzymes may utilize additional 
phosphonic acid substrates. Preliminary testing of alternative substrate utilization (Fig 
3.12) by PcxL and HpxL suggest that these enzymes do preferentially catalyze the 
oxidation of 2AEPn and 1H2AEPn because the catalytic efficiencies of these enzymes 
with the other phosphonic acid substrates is much lower (Table 3.6). However, these 
enzymes appear to be able to utilize other phosphonic acid substrates. This suggests there 
is some substrate tolerance of the enzymes and further investigations may provide a way 










Table 3.6. Initial rate kinetics for HpxL and PcxL using alternative substrates. Rates were 
determined by monitoring NADPH consumption on a UV-Vis spectrophotometer. Vmax, 
Km, and Ki were determined by fitting the data with either Michaelis-Menten (no 
substrate inhibition observed) or substrate inhibition models (substrate inhibition model 
was used when a Ki was determined). Reaction components included: 50 mM sodium 
phosphate buffer, pH 7.8, 300 µM NADPH, 50 µM FAD, and substrate ranging from 1 
mM to 160 mM. Enzyme concentrations of 5 µM for PcxL and 5 µM or 10 µM for HpxL 
were used. The substrates used were pure phosphonoalanine, l-1-aminoethylphosphonic 
acid (L-alaP), or aminomethylphosphonic acid (AMPn). This experiment was performed 
in triplicate for each curve. 
 










Phosphonoalanine 1.61 ± 3.43 161 ± 369 10 11 ± 28 
L-alaP 0.209 ± 0.009 21 ± 4 10 n/a 
AMPn 0.45 ± 0.02 23 ± 3 20 n/a 
HpxL AMPn 0.050 ± 0.002 1.7 ± 0.2 30 45 ± 4 
 
 
Figure 3.12. Kinetic curves of PcxL or HpxL in the presence of different phosphonic 
acid substrates. The kinetic constants extracted from each curve are shown in Table 3.6. 
(A) HpxL using AMPn as a substrate. (B) PcxL using AMPn as a substrate. (C) PcxL 
using phosphonoalanine as a substrate. (D) PcxL using L-alaP as a substrate. 
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 Streptomyces regensis NRRL WC-3744 has been shown to produce both 
hydroxynitrilaphos and hydroxyphosphonocystoximic acid (11, 21). We are still unsure 
of the final natural product of the hpx biosynthetic gene cluster and whether this product 
is bioactive. There is a possibility that hydroxyphosphonocystoximate is an off-pathway 
intermediate that is produced by the strain and that hydroxynitrilaphos is the final, 
bioactive molecule produced by these strains. We believe that phosphonocystoximate 
may be made in a similar biosynthetic route as glucosinolates in plants based on the 
putative functions of some of the proteins of these biosynthetic gene clusters (11, 21). 
Based on the biosynthesis of glucosinolates in plants, nitrile-containing compounds are 
not an uncommon product of these biosynthetic pathways (17). Therefore, we 
hypothesize that hydroxynitrilaphos may be a by-product that is similar to by-products 
observed in glucosinolate biosynthesis.  
 The bioactivity of the phosphonocystoximates and hydroxynitrilaphos is unknown 
due to the lack of sufficient material isolated from the producing organisms (11, 21). The 
logical next step would be testing the bioactivity of these compounds to determine 
whether they show potent bioactivity like other small molecules containing an oxime 
moiety (37). Glucosinolates, and their degradation products, have been shown to have 
antifungal (40), antibacterial (1, 38), and insect repellant (43) activities. In particular, it 
has been noted in numerous studies that the isothiocyanate degradation product is the 
toxic by-product that displays bioactivity, not the glucosinolate itself. This would be a 
new mechanism of Trojan horse-like bioactivity for phosphonate natural products if these 
small molecules have a similar toxic breakdown product. Therefore, it is prudent to 
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determine whether the phosphonocystoximic acids or hydroxynitrilaphos show 
bioactivity and if these molecules function in a similar manner to glucosinolates.  
3.5 MATERIALS AND METHODS 
3.5.1 General experimental procedures 
Nuclear Magnetic Resonance (NMR) spectra were collected using an Agilent 
Technologies 600 MHz NMR spectrometer with D2O as the lock solvent (minimum 20% 
v/v). All chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, 
MO) unless otherwise noted.  
3.5.2 N-oxidase cloning, overexpression, and purification 
The genes encoding the N-oxidases were amplified via PCR using primer pairs 
MG140 (5’-CTGGTGCCGCGCGGCAGCCATATGacgaccgacaattccccagcca-3’) and 
MG141 (5’-AGTGGTGGTGGTGGTGGTGCTCGAGtcatgcgggggtcctttcgatgtcc-3’) for 
hpxL and primer pairs MG142 (5’-
CTGGTGCCGCGCGGCAGCCATATGcgttccaaccgactcgccatcgtcg-3’) and MG143 (5’-
AGTGGTGGTGGTGGTGGTGCTCGAGtcacactcccgtggtgatgcgcgcg-3’) for pcxL from 
fosmids containing the phosphonocystoximic acid gene clusters (21). The plasmid, 
pET28B, was amplified using primers pET28-NdeI-R (5’-
CATATGGCTGCCGCGCGGCACCAGGCCGCTG-3’) and pET28B-XhoI-F (5’-
CTCGAGCACCACCACCACCACCACTGAGATCCGG-3’). Uppercase letters 
represent sequence homologous to the plasmid, pET28B, underlined sequence is an 
inserted restriction enzyme site, and the lowercase letters represent sequence homology to 
the gene to be amplified. The primer pair MG140 and MG141 were designed to mutate 
the GTG start codon of hpxL to an ATG start codon for expression in Escherichia coli. 
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The gene fragments were subsequently cloned into pET28B using Gibson Assembly
®
 
(New England Biolabs, Ipswich, MA) to yield pMNG016 for hpxL and pMNG017 for 
pcxL. The sequences were verified at the UIUC Core Sequencing Facility.  
The PcxL and HpxL proteins were affinity-purified after expression in E. coli. 
PcxL and HpxL were overexpressed in transformed E. coli Rosetta DE3 cells containing 
either plasmid pMNG016 or pMNG017. Proteins were purified using one of two 
methods. Method one involved cells grown in Studier’s ZYM5052 autoinduction medium 
(41) with the following modification: the trace elements solution was replaced with 1 
mg/L of each iron(II) sulfate heptahydrate, zinc(II) sulfate heptahydrate, and 
manganese(II) chloride dihydrate. The cultures were shifted to 18°C when the optical 
density (OD600) reached 0.6-0.8 and protein was overexpressed for 16 hours. Cells were 
collected via centrifugation and resuspended in lysis buffer (300 mM sodium chloride, 50 
mM sodium phosphate (dibasic), 10% glycerol and 10 mM imidazole, pH 8.0). The cell 
suspension was mixed with 1 mg/mL lysozyme, 100 units DNase I, and 100 μg RNase A 
and mixed for 30 minutes at 4°C. The cell suspension was passed two times through a 
French Press cell disruptor (Thermo Electron Corporation, Waltham, MA) at 1000 psi. 
The suspension was centrifuged at 14,000 x gravity (g) for a minimum of 30 minutes and 
the pellet was discarded. The liquid portion was passed over a 5 mL HisTrap FPLC 
protein column (GE Healthcare Life Sciences, Marlborough, MA) and washed with lysis 
buffer until the protein was no longer eluting from the column as determined by 
absorbance at A260 nm. Protein was eluted from the column on an ÄTKApurifier FPLC 
(GE Healthcare Life Sciences, Marlborough, MA) using a gradient from 10 mM – 250 
mM imidazole with 60 column volumes over one hour at a flow rate of 5 mL/min. 
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Fractions containing purified protein, as determined by running the samples on a SDS-
PAGE gel, were pooled, and concentrated using a 30 kDa molecular weight Amicon
®
 
Ultra spin filter (EMD Millipore, Burlington, MA). Method two involved cells grown in 
Luria Broth until the optical density (OD600) reached 0.6-0.8. The cultures were chilled on 
ice for 30 minutes and protein expression was induced upon the addition of Isopropyl β-
D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Cells were shaken at 
18°C for 16 hours after induction. Pelleted cells were resuspended in lysis buffer (see 
above) containing 1 mg/mL lysozyme, 100 units DNase I, and 100 μg RNase A and 
mixed at 4°C for 30 minutes. The cell suspension was passed two times through a French 
Press cell disruptor (Thermo Electron Corporation, Waltham, MA) at 1000 psi. The 
suspension was centrifuged at 14,000 x g for 30 minutes and the pellet was discarded. 
The soluble fraction containing soluble protein was mixed with 5 mL of loose Ni-NTA 
resin for 30 minutes at 4°C. The resin was washed with wash buffer (300 mM sodium 
chloride, 50 mM sodium phosphate (dibasic), 10% glycerol and 20 mM imidazole, pH 
8.0) until protein was no longer eluting from the resin as determined by absorbance at 
A260 nm. Protein was eluted from the column by incubating the resin with elution buffer 
(300 mM sodium chloride, 250 mM sodium phosphate (dibasic), 10% glycerol and 20 
mM imidazole, pH 8.0) for 15 minutes and collecting the flow through. This flow 
through was concentrated using a 30 kDa molecular weight Amicon
®
 Ultra spin filter 
(EMD Millipore, Burlington, MA). All samples, regardless of which purification method 
was used, were exchanged into storage buffer (300 mM sodium chloride, 50 mM sodium 
phosphate (dibasic), and 10% glycerol) using a PD-10 desalting column (GE Healthcare 
Life Sciences, Marlborough, MA). 
105 
 
3.5.3 Bioinformatics characterization of HpxL and PcxL 
 The following amino acid sequences were downloaded from NCBI: HpxL 
(accession number WP_030990682.1), PcxL (accession number WP_051704824.1), 
AzmF (accession number AMQ23503.1), ClmM (accession number CCC55915.1), 
CrmH (accession number AFD30961.1), AlmD (accession number CCA29200.1), FzmM 
(accession number WP_053787792.1), and CreE (accession number ALA99202.1). 
These sequences were aligned using the standard settings for a MUSCLE alignment using 
Geneious (23) (Geneious version 8.1.2), which provided the percent identity between the 
proteins for Table 3.2.  
3.5.4 Cofactor preference of the PcxL and HpxL 
Cofactor preference experiments were monitored using an Cary 4000 UV-Vis 
spectrophotometer (Agilent, Santa Clara, CA). NADH and NADPH consumption was 
monitored by observing the absorption at 340 nm. Reaction components included: 50 
mM sodium phosphate buffer, pH 7.8, 300 µM nicotinamide cofactor (either NADPH or 
NADH), 50 µM flavin cofactor (FAD or FMN), 10 mM 2AEPn and 10 µM N-oxidase 
(PcxL or HpxL). Reaction components except for substrate and enzyme were mixed in a 
200 μL quartz cuvette. Enzyme was added and the background rate of the enzyme was 
collected for approximately one minute. Reactions were initiated upon addition of 2AEPn 
and three replicates were collected for each condition. 
3.5.5 Flavin identification 
HpxL (13.8 mg) and PcxL (5.4 mg) stocks were brought to room temperature and 
concentrated to 50 μL using a 30 kDa molecular weight Amicon
®
 Ultra spin filter (EMD 
Millipore, Burlington, MA) and the flow through was discarded. Protein was washed six 
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times with 500 μL ddH2O. At the end of washing, PcxL was colorless, while HpxL 
retained some bound flavin as noted by the yellow color of the protein. Collected flavin 
was flash frozen and placed on a lyophilizer until dry. The flavin was resuspended in 
ddH2O. We determined the concentration of the flavins based on absorbance at 450 nm, 




for FAD (HpxL extracted flavin = 
37.1 μM and PcxL extracted flavin = 30.9 μM). Extracted flavin (10 μL) was injected 
onto a 150 x 4.6 mm 4-micron Synergi 4u Fusion-RP column connected to an Agilent 
1200 series LC/MSD SL mass spectrometer (Agilent, Santa Clara, CA) monitoring for 
the masses corresponding to FAD (m/z = 786.2) and FMN (m/z = 457.1) in positive 
mode. The following solvents were used: A = 95% ddH2O / 5% acetonitrile with 0.1% 
formic acid and B = 5% ddH2O / 95% acetonitrile with 0.1% formic acid. The sample 
was run with a linear gradient from time 0-12 minutes: time 0  min = 5% B, 12 min = 
95% B, 15 min = 95% B, 18 min = 5% B, and 25 min = 5% B. Flow rate was 1 mL / 
minute. 
HpxL (3.6 mg) and PcxL (6.1 mg) stocks were used to determine the absorption 
spectra of the proteins on a Cary 4000 UV-Vis spectrophotometer (Agilent, Santa Clara, 
CA) scanning from 200 nm – 800 nm. NADPH was added to the protein to a final 
concentration of 500 μM and the absorption spectrum of the protein was measured after 







3.5.6 Stoichiometry determination 
Oxygen consumption was monitored on a Clark-type oxygen electrode 
(Hansatech Instruments, Norfolk, England). NADPH consumption was monitored (A340) 
on an Cary 4000 UV-Vis spectrophotometer (Agilent, Santa Clara, CA). Reaction 
components included 50 mM sodium phosphate buffer (air-saturated), pH 7.8, 300 µM 
NADPH, 50 µM FAD, 50 mM 2AEPn, and 1 µM PcxL or 5 µM HpxL. Reactions were 
initiated by addition of enzyme and monitored for 5 minutes. Three replicates were 
performed on each instrument. The number of moles of both oxygen and NADPH 
consumed by the enzyme in 5 minutes was determined and compared. 
NADPH consumption was determined using a Cary 4000 UV-Vis 
spectrophotometer (Agilent, Santa Clara, CA) and via 
31
P NMR. 2AEPn consumption 
was determined using 
31
P NMR. Reaction components included 50mM sodium phosphate 
buffer (air-saturated), pH 7.8, 3 mM NADPH, 500 µM FAD, 5 mM 2AEPn, and 25 µM 
PcxL or 25 µM HpxL. Three replicates were performed. The reactions incubated for 30 
minutes at room temperature and were quenched using one reaction volume of 100% 
methanol. Dimethylphosphinic acid was added to the reaction as an internal 
quantification standard to yield a final concentration of 10 mM. The number of mols of 
substrate and NADPH consumed were determined and directly compared. 
3.5.7 Generation of (S)-1H2AEPn by HpxV 
To yield an N-terminal 6xHis-tagged HpxV, hpxV was amplified using the 
primers Orf10_LIC_F (5’-TACTTCCAATCCAATGCAcctactcacccacgcactc-3’) and 
Orf10_LIC_R (5’-TTATCCACTTCCAATGTTATTActacttgctcgaccacatg-3’) and was 
cloned into the ligation independent cloning vector pET His6 TEV LIC cloning vector 
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(2B-T). N6xHis-HpxV was overexpressed in transformed Escherichia coli BL21 DE3 
containing the pET His6 TEV LIC cloning vector (2B-T) with hpxV. HpxV was 
overexpressed and purified using method two as described above. (S)-1H2AEPn was 
generated using HpxV, a 2AEPn-dependent α-ketoglutarate-dependent dioxygenase from 
S. regensis NRRL WC-3744. The reactions contained 50 mM phosphate buffered saline, 
pH 7.4, 40 mM α-ketoglutarate, 1 mM iron (II) ammonium sulfate, 7.5 mM 2AEPn, 4 
mM L-ascorbic acid, and 200 µM HpxV. Reactions were incubated for 13 hours at 30°C. 
The reaction was quenched by precipitating the protein by addition of methanol to yield a 
90% methanol precipitation. Precipitated protein was removed via centrifugation and the 
reaction mixture was concentrated on a rotary evaporator. The concentration of 
1H2AEPn generated was determined by 
31
P NMR spectroscopy, using phosphite as an 
internal reference standard for quantification at a final concentration of 10 mM. In some 
experiments synthetic (S)-1H2AEPn was used (see below). 
3.5.8 Product formation experiments 
HpxL or PcxL were incubated with 2AEPn or HpxV-generated (S)-1H2AEPn to 
monitor what products are formed by the N-oxidases. The reactions were set up with the 
following components: 25 mM sodium phosphate buffer, pH 7.8, 500 µM NADPH, 100 
µM FAD, 25 µM PcxL or HpxL, 10 μM phosphite dehydrogenase, 25 mM phosphite, 
and 3 mM of substrate at pH 7.8. Reactions were incubated for 16 hours at room 
temperature. Product formation was monitored using 
31







H HMBC spectroscopy. A mutated phosphite dehydrogenase 
(PTDH17x) that can use either NADH or NADPH as the nicotinamide coenzyme(47) was 
used to regenerate NADPH in the substrate specificity experiments. This enzyme was 
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overexpressed in E. coli BL21 DE3 cells containing a plasmid with PTDH17x cloned into 
pET15b. Cells were grown in modified Studier’s ZYM5052 medium (as described above) 
at 37°C until OD600 reached 0.6-0.8, the culture was shifted to 18°C, and protein was 
overexpressed for 16 hours. The cell suspension was passed two-times through a French 
Press cell disruptor (Thermo Electron Corporation, Waltham, MA) at 1000 psi. The 
suspension was centrifuged at 14,000 x g for a minimum of 30 minutes and the pellet was 
discarded. Soluble cell lysate was passed over free Ni-NTA IMAC resin and washed with 
wash buffer (20 mM Tris-HCl, 500 mM NaCl, and 10% glycerol (% v/v), pH 7.6). Bound 
protein was washed stepwise with the wash buffer containing increasing levels of 
imidazole at concentrations of 10 mM, 25 mM, and 50 mM respectively until there was 
no protein detected by monitoring A260 nm. Protein was eluted from the column using 
wash buffer containing 250 mM imidazole, concentrated using a 10 kDa molecular 
weight Amicon
®
 Ultra spin filter (EMD Millipore, Burlington, MA). The protein was 
exchanged into protein storage buffer (50 mM HEPES, 200 mM KCl, and 10% glycerol 
(% v/v), pH 7.5) using a PD-10 desalting column (GE Healthcare Life Sciences, 
Marlborough, MA).  
3.5.9 Stereospecific synthesis of (R)- and (S)-1H2AEPn 
Enantiopure (ee> 99%) (R)- and (S)-1H2AEPn was generated following 







3.5.10 Kinetic assays 
Enzyme assays were monitored using a Cary 4000 UV-Vis spectrophotometer 
(Agilent, Santa Clara, CA). NADPH consumption was monitored by observation of the 
absorption at 340 nm. Reaction components included: 50 mM sodium phosphate buffer, 
pH 7.8, 300 µM NADPH, 50 µM FAD, substrate concentrations ranging from 62.5 µM to 
150 mM and enzyme concentrations of 1 µM or 5 µM for PcxL and 5 µM or 10 µM for 
HpxL. Briefly, reaction components except for substrate and enzyme were mixed in a 
200 μL quartz cuvette. Enzyme was added and the background rate of the enzyme was 
collected for approximately one minute. Reactions were initiated upon addition of 
substrate. Three replicates were obtained for each concentration of substrate. Due to the 
time it takes to complete one NADPH consumption curve for HpxL (between 15-30 
minutes), all the initial rates are approximate initial rates. The rate over approximately 30 
seconds once the enzyme reaches steady-state was read and this was used as the “initial 
rate”. 
3.5.11 Construction of phylogenetic trees and assignment of genomic neighborhoods 
To construct the N-oxidase phylogenetic tree, the top 500 BLAST (2) hits 
obtained using HpxL (WP_030990672.1) as a query sequence were downloaded on 
February 18
th
, 2017. These sequences were aligned using MAFFT with default settings 
(22) and the maximum likelihood tree was constructed using FastTree using default 
settings (36). Accession numbers of the 500 amino acid sequences used in the tree were 
run through RODEO (44) to identify putative N-oxidase proteins involved in a 
phosphonate gene cluster. A positive hit constitutes a phosphoenolpyruvate mutase 
enzyme being within 15 genes upstream or downstream of the N-oxidase.  
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To construct the PepM phylogenetic tree, five Actinobacteria PepM amino acid 
sequences were used as a BLAST query (21): Streptomyces luridus PepM (ACZ13456), 
Streptomyces viridochromogenes (AAU00071), Streptomyces fradiae (ACG70831), 
Strepomyces rubellomurinus (ABB90393), and Streptomyces regensis HpxU 
(WP_030646403.1). The search was limited to Actinobacteria, with Mycobacteria being 
excluded from the search. All hits for each search were sorted to remove duplicates and 
the characteristic EDKxxxxxNS motif was manually identified to distinguish actual 
PepMs from other members of the isocitrate lyase superfamily (9, 32, 48). There were 
199 amino acid sequences identified using this approach as putative PepMs. These amino 
acid sequences were aligned using MAFFT (22) and the maximum likelihood tree was 
constructed using FastTree (36). RODEO (44) was used to identify phosphonate gene 
clusters that contain an N-oxidase homolog. A positive hit constitutes an N-oxidase being 














1.  Aires A, Mota VR, Saavedra MJ, Monteiro AA, Simões M, et al. 2009. Initial in 
vitro evaluations of the antibacterial activities of glucosinolate enzymatic hydrolysis 
products against plant pathogenic bacteria. J. Appl. Microbiol. 106(6):2096–2105. 
2.  Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local 
alignment search tool. J. Mol. Biol. 215(3):403–10. 
3.  Anderson VE, Weiss PM, Cleland WW. 1984. Reaction intermediate analogs for 
enolase. Biochemistry. 23(12):2779–86. 
4.  Arabshahi L, Schmitz FJ. 1987. Brominated tyrosine metabolites from an 
unidentified sponge. J. Org. Chem. 52(16):3584–86. 
5.  Bacher M, Brader G, Hofer O, Greger H. 1999. Oximes from seeds of Atalantia 
ceylanica. Phytochemistry. 50(6):991–94. 
6.  Bennett R, Donald A, Dawson G, Hick A, Wallsgrove R. 1993. Aldoxime-Forming 
Microsomal Enzyme Systems Involved in the Biosynthesis of Glucosinolates in 
Oilseed Rape (Brassica napus) Leaves. Plant Physiol. 102(4):1307–12. 
7.  Bennett RN, Kiddle G, Hick AJ, Dawson GW, Wallsgrove RM. 1996. Distribution 
and activity of microsomal NADPH-dependent monooxygenases and amino acid 
decarboxylases in cruciferous and non-cruciferous plants, and their relationship to 
foliar glucosinolate content. Plant Cell Environ. 19(7):801–12. 
8.  Chen CCH, Zhang H, Kim AD, Howard A, Sheldrick GM, et al. 2002. Degradation 
Pathway of the Phosphonate Ciliatine:  Crystal Structure of 2-
Aminoethylphosphonate Transaminase,. Biochemistry. 41(44):13162–69. 
9.  Chen CM, Ye QZ, Zhu ZM, Wanner BL, Walsh CT. 1990. Molecular biology of 
carbon-phosphorus bond cleavage. Cloning and sequencing of the phn (psiD) genes 
involved in alkylphosphonate uptake and C-P lyase activity in Escherichia coli B. J. 
Biol. Chem. 265(8):4461–71. 
10.  Chen H-P, Zhao Z-Z, Li Z-H, Dong Z-J, Wei K, et al. 2016. Novel Natural Oximes 
and Oxime Esters with a Vibralactone Backbone from the Basidiomycete 
Boreostereum vibrans. ChemistryOpen. 5(2):142–49. 
11.  Cioni JP, Doroghazi JR, Ju K-S, Yu X, Evans BS, et al. 2014. Cyanohydrin 
Phosphonate Natural Product from Streptomyces regensis. J. Nat. Prod. 77(2):243–
49. 
12.  Cortina NS, Revermann O, Krug D, Müller R. 2011. Identification and 
Characterization of the Althiomycin Biosynthetic Gene Cluster in Myxococcus 
xanthus DK897. ChemBioChem. 12(9):1411–16. 
113 
 
13.  Du L, Lykkesfeldt J, Olsen CE, Halkier BA. 1995. Involvement of cytochrome 
P450 in oxime production in glucosinolate biosynthesis as demonstrated by an in 
vitro microsomal enzyme system isolated from jasmonic acid-induced seedlings of 
Sinapis alba L. Proc. Natl. Acad. Sci. U. S. A. 92(26):12505–9. 
14.  Dumora C, Lacoste A-M, Cassaigne A. 1983. Purification and Properties of 2-
Aminoethylphosphonate: Pyruvate Aminotransferase from Pseudomonas 
aeruginusa. Eur. J. Biochem. 133(1):119–25. 
15.  Eyer P. 2003. The Role of Oximes in the Management of Organophosphorus 
Pesticide Poisoning. Toxicol. Rev. 22(3):165–90. 
16.  Garcia I, Vior NM, González-Sabín J, Braña AF, Rohr J, et al. 2013. Engineering 
the Biosynthesis of the Polyketide-Nonribosomal Peptide Collismycin A for 
Generation of Analogs with Neuroprotective Activity. Chem. Biol. 20(8):1022–32. 
17.  Halkier BA, Gershenzon J. 2006. Biology and Biochemistry of Glucosinolates. 
Annu. Rev. Plant Biol. 57(1):303–33. 
18.  Hong S, Shin Y, Jung M, Ha MW, Park Y, et al. 2015. Efficient synthesis and 
biological activity of Psammaplin A and its analogues as antitumor agents. Eur. J. 
Med. Chem. 96:218–30. 
19.  Huang Z, Wang K-KA, Donk WA van der. 2016. New insights into the biosynthesis 
of fosfazinomycin. Chem. Sci. 7(8):5219–23. 
20.  Jang J-H, van Soest RWM, Fusetani N, Matsunaga S. 2007. Pseudoceratins A and 
B, Antifungal Bicyclic Bromotyrosine-Derived Metabolites from the Marine 
Sponge Pseudoceratina purpurea. J. Org. Chem. 72(4):1211–17. 
21.  Ju K-S, Gao J, Doroghazi JR, Wang K-KA, Thibodeaux CJ, et al. 2015. Discovery 
of phosphonic acid natural products by mining the genomes of 10,000 
actinomycetes. Proc. Natl. Acad. Sci. 112(39):12175–80. 
22.  Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software 
version 7: improvements in performance and usability. Mol. Biol. Evol. 30(4):772–
80. 
23.  Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, et al. 2012. Geneious 
Basic: An integrated and extendable desktop software platform for the organization 
and analysis of sequence data. Bioinformatics. 28(12):1647–49. 
24.  Kelley L. PHYRE2 Protein Fold Recognition Server. 
http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index. 
25.  Kelly WL, Townsend CA. 2002. Role of the Cytochrome P450 NocL in Nocardicin 
A Biosynthesis. J. Am. Chem. Soc. 124(28):8186–87. 
114 
 
26.  Kelly WL, Townsend CA. 2005. Mutational Analysis of nocK and nocL in the 
Nocardicin A Producer Nocardia uniformis. J. Bacteriol. 187(2):739–46. 
27.  Kim AD, Baker AS, Dunaway-Mariano D, Metcalf WW, Wanner BL, Martin BM. 
2002. The 2-Aminoethylphosphonate-Specific Transaminase of the 2-
Aminoethylphosphonate Degradation Pathway. J. Bacteriol. 184(15):4134–40. 
28.  Kim YS, Jeong H-Y, Kim AR, Kim W-H, Cho H, et al. 2016. Natural product 
derivative BIO promotes recovery after myocardial infarction via unique 
modulation of the cardiac microenvironment. Sci. Rep. 6:30726. 
29.  Lacoste AM, Dumora C, Balas L, Hammerschmidt F, Vercauteren J. 1993. 
Stereochemistry of the reaction catalysed by 2-aminoethylphosphonate 
aminotransferase. A 1H-NMR study. Eur. J. Biochem. 215(3):841–44. 
30.  Lin J, Cashman JR. 1995. N-Oxygenation of Phenethylamine to the trans-Oxime by 
Adult Human Liver Flavin-Containing Monooxygenase and Retroreduction of 
Phenethylamine Hydroxylamine by Human Liver Microsomes. J. Pharmacol. Exp. 
Ther. 282:1269–1279. 
31.  Liu N, Song L, Liu M, Shang F, Anderson Z, et al. 2015. Unique post-translational 
oxime formation in the biosynthesis of the azolemycin complex of novel ribosomal 
peptides from Streptomyces sp. FXJ1.264. Chem. Sci. 7(1):482–88. 
32.  Metcalf WW, van der Donk WA. 2009. Biosynthesis of Phosphonic and Phosphinic 
Acid Natural Products. Annu. Rev. Biochem. 78:65–94. 
33.  Moya P, Castillo M, Primo-Yúfera E, Couillaud F, Martínez-Máñez R, et al. 1997. 
Brevioxime:  A New Juvenile Hormone Biosynthesis Inhibitor Isolated from 
Penicillium brevicompactum. J. Org. Chem. 62(24):8544–45. 
34.  Pallitsch K, Happl B, Stieger C. 2017. Determination of the absolute configuration 
of (-)-hydroxynitrilaphos and related biosynthetic questions. Chem.  Eur. J. 23(62): 
15655-15665. 
35.  Pretsch E, Buhlmann P, Badertscher M. 2009. Structure Determination of Organic 
Compounds. 433 pp. 4th ed. 
36.  Price MN, Dehal PS, Arkin AP. 2010. FastTree 2 – Approximately Maximum-
Likelihood Trees for Large Alignments. PLoS One. 5(3):e9490. 
37.  Sánchez-Pujante PJ, Borja-Martínez M, Pedreño MÁ, Almagro L. 2017. 
Biosynthesis and bioactivity of glucosinolates and their production in plant in vitro 
cultures. Planta. 246(1):19–32. 
38.  Sotelo T, Lema M, Soengas P, Cartea ME, Velasco P. 2015. In Vitro Activity of 
Glucosinolates and Their Degradation Products against Brassica-Pathogenic 
Bacteria and Fungi. Appl. Environ. Microbiol. 81(1):432–40. 
115 
 
39.  Staalduinen LM van, McSorley FR, Schiessl K, Séguin J, Wyatt PB, et al. 2014. 
Crystal structure of PhnZ in complex with substrate reveals a di-iron oxygenase 
mechanism for catabolism of organophosphonates. Proc. Natl. Acad. Sci. 
111(14):5171–76. 
40.  Stotz HU, Sawada Y, Shimada Y, Hirai MY, Sasaki E, et al. 2011. Role of 
camalexin, indole glucosinolates, and side chain modification of glucosinolate-
derived isothiocyanates in defense of Arabidopsis against Sclerotinia sclerotiorum. 
Plant J. Cell Mol. Biol. 67(1):81–93. 
41.  Studier FW. 2005. Protein production by auto-induction in high density shaking 
cultures. Protein Expr. Purif. 41(1):207–34. 
42.  Sugai Y, Katsuyama Y, Ohnishi Y. 2016. A nitrous acid biosynthetic pathway for 
diazo group formation in bacteria. Nat. Chem. Biol. 12(2):73–75. 
43.  Textor S, Gershenzon J. 2009. Herbivore induction of the glucosinolate–myrosinase 
defense system: major trends, biochemical bases and ecological significance. 
Phytochem. Rev. 8(1):149–70. 
44.  Tietz JI, Schwalen CJ, Patel PS, Maxson T, Blair PM, et al. 2017. A new genome-
mining tool redefines the lasso peptide biosynthetic landscape. Nat. Chem. Biol. 
13(5):470-478. 
45.  Walsh CT, Wencewicz TA. 2012. Flavoenzymes: Versatile catalysts in biosynthetic 
pathways. Nat. Prod. Rep. 30(1):175–200. 
46.  Wong L, Radić Z, Brüggemann RJM, Hosea N, Berman HA, Taylor P. 2000. 
Mechanism of Oxime Reactivation of Acetylcholinesterase Analyzed by Chirality 
and Mutagenesis. Biochemistry. 39(19):5750–57. 
47.  Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JAV, et al. 2006. 
Heterologous Production of Fosfomycin and Identification of the Minimal 
Biosynthetic Gene Cluster. Chem. Biol. 13(11):1171–82. 
48.  Yu X, Doroghazi JR, Janga SC, Zhang JK, Circello B, et al. 2013. Diversity and 
abundance of phosphonate biosynthetic genes in nature. Proc. Natl. Acad. Sci., p. 
201315107. 
49.  Zhu Y, Zhang Q, Li S, Lin Q, Fu P, et al. 2013. Insights into Caerulomycin A 
Biosynthesis: A Two-Component Monooxygenase CrmH-Catalyzed Oxime 





Chapter 4: Biosynthesis of the broad-spectrum herbicide, phosphonothrixin 
 
4.1 INTRODUCTION 
4.1.1 Phosphonic acids used as herbicides 
Phosphonic acids have renowned success as herbicides. Glyphosate, trademarked 










, is one of 
the most widely used herbicides available on the market today and was developed by 
Monsanto in 1970 (8). This synthetic phosphonate is a transition-state analog of 
phosphoenolpyruvate and targets enolpyruvylshikimate-3-phosphate (EPSP) synthase, 
which is part of the shikimate pathway of aromatic amino acid biosynthesis (32). There 
are now a plethora of RoundUp Ready® crops containing a glyphosate-resistant copy of 
EPSP synthase in order to make weed-treatment easy for farmers (12). Upwards of 90% 
of cotton, maize, and soybeans planted in 2014 were RoundUp Ready®, glyphosate-
resistant crops (3).  
Phosphinothricin, also known as glufosinate, is trademarked under the names of 
Finale®, Basta®, and Liberty®. This natural product was first identified to be produced 
by Streptomyces viridochromogenes Tü494 (2) and Streptomyces hygroscopicus (26). 
Phosphinothricin mimics the tetrahedral intermediate of glutamine synthase (13). Like 
glyphosate, glufosinate is a potent herbicide (14), with many crops engineered containing 
the phosphinothricin acetyltransferase gene (bar or pat) under the trademarks 
LibertyLink® and WideStrike®. In Streptomyces, this gene confers self-resistance to 
phosphinothricin (23, 35). Because of the wide-spread use of these compounds, resistance 
to these herbicides is rapidly increasing. Recent studies have found that levels of 
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glyphosate and glufosinate resistance in weeds is rising, along with almost all other 
herbicides used on the market today. Resistance has been observed for 22 out of the 25 
different classes of herbicides used (20). Currently, estimates on global crop production 
suggest that weeds cause an annual crop loss of approximately 12% (27) and cost the 
agriculture industry on average two billion USD each year (20), and this cost will likely 
rise with an increase in the number of herbicide-resistant weeds. For this reason, we are 
in need of new herbicidal compounds for use in agriculture. 
4.1.2 Phosphonothrixin 
Phosphonothrixin was originally discovered in 1995 by Takahashi and colleagues 
during a search for novel herbicides (18, 34). Like glyphosate and phosphinothricin, this 
compound shows broad spectrum herbicidal activity against a variety of different weed 
(34); however, the mode of action of phosphonothrixin remains unknown. Initial reports 
hypothesized that phosphonothrixin may target 1-deoxyxylulose 5-phosphate 
reductoisomerase (DXR) because of its structural similarity to the deoxyxylulose 
phosphate (DXP), but this was shown to not be the target of phosphonothrixin in 
peppermint secretory cells (19). Due to the lack of understanding of the biosynthesis and 
mode-of-action of phosphonothrixin, development of this compound into a commercially 
viable herbicide currently seems unlikely. Identification of the biosynthetic gene cluster 
in 2014 by Lin and colleagues from Saccharothrix sp. ST-888 (21) was a major step for 
characterization of the biosynthesis of this compound. Upon discovery of the genes 
required for the biosynthesis of this compound, it might be possible to identify other 
organisms that contain the potential to produce phosphonothrixin at higher levels than 
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Saccharothrix sp. ST-888 or to identify a resistance gene for this compound if the target 
is conserved among diverse organisms. 
4.1.3 Biosynthesis of phosphonothrixin 
The phosphonate gene cluster in Saccharothrix sp. ST-888 appears very different 
than characterized phosphonate biosynthetic pathways. This gene cluster lacks 
homologous enzymes to the two known enzymes used to convert phosphonopyruvate into 
one of two known products, driving the highly unfavorable PEP mutase reaction forward 
(5): there are no phosphonopyruvate decarboxylase (31) or phosphonomethylmalate 
synthase (9) homologs within the gene cluster. Lin and colleagues identified the minimal 
biosynthetic gene cluster through heterologous expression and have proposed a 
phosphonothrixin biosynthetic scheme that includes the condensation of 
phosphonopyruvate with pyruvate by a thiamine pyrophosphate-dependent enzyme (21). 
This chapter will focus on the characterization of the phosphonothrixin biosynthetic gene 
cluster and will provide evidence for an alternative biosynthetic pathway for 
phosphonothrixin biosynthesis. 
4.2 RESULTS AND DISCUSSION 
4.2.1 The phosphonothrixin gene cluster and identification of other organisms with 
the genetic capacity to produce phosphonothrixin 
 Sequencing and identification of the phosphonothrixin gene cluster in 
Saccharothrix sp. ST-888 allowed us to identify other organisms that have the potential 
to produce phosphonothrixin. In total, 16 different organisms contain the genes that share 
>75% amino acid identity with those found in the Saccharothrix sp. ST-888 
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phosphonothrixin gene cluster (data not shown). The synteny and organization for 
fourteen of these gene clusters are identical to the Saccharothrix sp. ST-888 gene cluster 
(Fig 4.1). One organism, Saccharopolyspora spinosa NRRL 18395, contains many of the 
genes required for phosphonothrixin biosynthesis, although the amino acid identity of 
these proteins is much lower than the other 14 organisms with the phosphonothrixin gene 
cluster. 
 
Figure 4.1. The phosphonothrixin gene cluster from Saccharothrix sp. ST-888 and 
putative phosphonothrixin gene cluster from Saccharopolyspora spinosa NRRL 18395. 
4.2.2 In vitro testing of the function of the acetolactate synthase homolog, FtxF
2
 
 Lin and colleagues suggest that phosphonothrixin biosynthesis proceeds through 
the condensation of phosphonopyruvate (PnPy) and pyruvate, which can subsequently be 
reduced to form phosphonothrixin (21). We hypothesized that one of the enzymes that 
might catalyze this reaction is the thiamine pyrophosphate (TPP)-dependent acetolactate 
synthase homolog, FtxF. TPP-dependent enzymes catalyze carbon-carbon bond 
formation through the oxidative condensation of two ketone-containing molecules (6). To 
test this hypothesis, we incubated 6xHis-tagged FtxF from Saccharothrix sp. ST-888 in 
                                                          
2 I would like to thank Michael Steven Carter for the Bacillus subtilis ALS protein and 
Shihui Dong for the construction of the FtxF expression plasmid and protein. 
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the presence of a previously characterized PEP mutase homolog, RhiH (4), PEP and 
pyruvate. With this reaction mixture, we do not observe conversion of PEP into any 
product (Fig 4.2). However, when we incubate PEP with RhiH (4) and the 
phosphonopyruvate decarboxylase from Bacteroides fragilis (Bf-Ppd) (36), we see nearly 
complete conversion of PEP into phosphonoacetaldehyde (Fig 4.2), which indicates that 
RhiH is actively converting PEP into phosphonopyruvate. Therefore, it is likely that if the 
substrate for FtxF were phosphonopyruvate, we should see conversion of PEP into 
another compound corresponding to the appearance of a new peak in the 
31
P NMR 
spectrum. Thus, we do not believe that phosphonopyruvate is the in vivo substrate of 
FtxF.  
 
Figure 4.2. Reaction of FtxF from Saccharothrix sp. ST-888 with PEP in the presence of 
RhiH (top). Reaction of RhiH with phosphonopyruvate decarboxylase from Bacteroides 
fragilis (Bf-Ppd) (bottom). The reactions were set up with the following conditions in 50 
mM HEPES buffer with 10 mM magnesium chloride, pH 7.5: 10 mM PEP, 50 μg of each 
enzyme, 1 mM TPP, and 10 mM sodium pyruvate (ALS reaction only).  
Dihydroxypropylphosphonic acid (DHPPA) is a compound isolated from the 
extracts of Saccharothrix sp. ST-888 (will be discussed in section 4.2.4). Based on the 
observation that FtxF does not utilize phosphonopyruvate, I tested the idea that DHPPA 
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may be a substrate for this enzyme. To do this, I incubated FtxF with DHPPA and sodium 
pyruvate, but again was unable to detect any product formation (Fig 4.3).  
 
Figure 4.3. Reaction of FtxF from Saccharothrix sp. ST-888 with DHPPA and pyruvate. 
The reactions were set up with the following conditions in 50 mM HEPES buffer with 10 
mM magnesium chloride, pH 7.5: 500 μM DHPPA, 50 μg FtxF, 1 mM TPP, and 1 mM 
sodium pyruvate. 
 After determining that FxF does not use DHPPA or phosphonopyruvate as a 
substrate with pyruvate, I tested the idea that FtxF might be a bonafide acetolactate 
synthase (ALS), which is the first committed step of branch-chain amino acid 
biosynthesis. ALS condenses two molecules of pyruvate together to form acetolactate (6). 
Thus, I incubated FtxF with pyruvate. While we observed formation of acetolactate with 
FtxF from either Saccharothrix sp. ST-888 or S. spinosa NRRL 18395, FtxF did not form 
as much acetolactate as a canonical acetolactate synthase enzyme isolated from Bacillus 
subtilis (Fig 4.4). It should be noted that these reactions are end-point monitoring of 
product formation and give us little indication of the rate of the reactions, so it is 





Figure 4.4. Acetolactate production by FtxF from Saccharothrix sp. ST-888, 
Saccharopolyspora spinosa NRRL 18395, or an acetolactate synthase from Bacillus 
subtilis. The Westerfeld acetoin detection assay(33) was used to determine if acetolactate 
was formed by the enzymes by measuring levels of acetoin after chemical oxidative 
decarboxylation of acetolactate. Reactions were set up with the following components in 
100 mM potassium phosphate buffer pH 7.5: 20 mM sodium pyruvate, 237 μM thiamine 
pyrophosphate, 10 mM magnesium chloride. Reactions were performed in duplicate. 
Based on these data, we propose two hypotheses for the function of FtxF. The 
first is that FtxF may utilize pyruvate as at least one of its substrates and the other may be 
a phosphonic acid that we have not yet identified. Second, FtxF may only utilize pyruvate 
as a substrate. Structurally, phosphonothrixin is similar to acetolactate (Fig 4.5). If 
phosphonothrixin is an inhibitor of acetolactate synthase, which is required for the 
biosynthesis of branched-chain amino acids in bacteria (22), the host organism would 
need a way to provide self-resistance to this compound during its biosynthesis. One way 
to provide this is to encode a copy of the target that is unable to be inhibited by 
phosphonothrixin. Saccharothrix sp. ST-888 encodes several acetolactate synthase 
homologs within its genome (data not shown), which suggests that FtxF is not the 
canonical ALS responsible for branched-chain amino acid biosynthesis. Even though 
activity of the enzyme appears lower than a canonical acetolactate synthase from another 
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organism (Fig 4.4), there is some function of the enzyme. This is consistent with 
resistance proteins found in other natural product gene clusters.  A producing organism 
may produce a resistant copy of the target protein that cannot be inhibited by the natural 
product (15).  
 
Figure 4.5. Structures of phosphonothrixin and acetolactate. 
4.2.3 Phylogeny of FtxF shows it is related to acetolactate synthase proteins 
To examine the relatedness of FtxF to proteins with known function, we 
performed a BLAST (24) search against the Swiss-Prot/UniProt database using 
Saccharothrix sp. ST-888 FtxF (Accession number WP_045300935.1). FtxF shareas a 
common ancestor with acetolactate synthase proteins (Fig 4.6). However, when 
performing a BLAST search using FtxF as a query against the non-redundant database, 
we find that none of the proteins on the Swiss-Prot tree are represented, and only 
uncharacterized enzymes are retrieved from BLAST when looking for the closest 250 
homologs to FtxF (Fig 4.7). These data do not help support nor contradict our two 
hypotheses proposed for the function of FtxF in vivo, because we observe that FtxF 
shares a common ancestor with canonical ALS proteins; however, these proteins are not 
the closest homologs of FtxF in the NCBI database. Section 4.2.6 will detail experiments 




Figure 4.6. Maximum-likelihood phylogenetic tree of FtxF homologs found within the 
SwissProt/UniProt database. Green represents FtxF proteins. Light green represents 
sulfoacetylaldehyde acetyltransferases, pink shows pyruvate oxidases, blue represents 
acetolactate synthase, light blue are pyruvate decarboxylases, orange represents 3D-
(3,5/4)-trihydroxycyclohexane-1,2-dione (THcHDO) hydrolases, light orange are 2-





Figure 4.7. Maximum-likelihood phylogenetic tree the top 250 homologs of FtxF in the 
NCBI non-redundant database(16). Green represents FtxF proteins.  
4.2.4 Saccharothrix sp. ST-888 produces DHPPA and phosphonothrixin
3
 
 To further characterize phosphonothrixin biosynthesis, we examined the different 
phosphonic acids produced by Saccharothrix sp. ST-888. When grown in GUBC and 
R2AS media, Saccharothrix sp. ST-888 produces over ten phosphonic acids (data not 
shown). Two of these, were identified as phosphonothrixin and 
dihydroxypropylphosphonic acid (DHPPA) (Fig 4.8 and Fig 4.9), based on spectroscopic 
data (Fig 4.9) (Table 4.1) (16) (Fig 4.9) (Table 4.2) (10). 
                                                          
3 I would like to thank Ryuichi Hirota for collaboration on this project. Scale up and 










H NMR spectrum of compounds isolated from Saccharothrix sp. ST-888. 
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The 2D-NMR experiments are shown in Fig 4.18 – Fig 4.21. 
                                  
No. δC, mult δH (J in Hz) COSY HMBC 
1 32.2, CH2 1.68, m (17.4, 10.2, 6.7) 2 2, 3 
2 68.3, CH 3.87, m (10.1, 6.7, 3.5) 1, 3 1, 3 
3 65.9, CH2 
3.37, dd (11.8, 6.8) 3.56, dd 
(11.8 , 3.6) 
2 1, 2 
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correlations. The 2D-NMR experiments are shown in Fig 4.18 – Fig 4.21. 
                          
No. δC, mult δH (J in Hz) COSY HMBC 
1 32.8, CH2 
1.83, dd (16.8, 15.3) 2.03, dd 
(17.6, 15.4) 
- 2, 3 
2 80.8, qC - - - 
3 215.4, qC - - - 
4 26.0, CH3 2.21, s - 2, 3 
3' 67.7, CH2 3.52, d (11.8) 3.71, d (11.8) - 2, 4 




 Isolation of DHPPA and phosphonothrixin from the same extract suggests that 
DHPPA is involved in the biosynthesis of phosphonothrixin. DHPPA is also a putative 
intermediate in the biosynthesis of valinophos (Fig 1.12), isolated from culture extracts of 
Streptomyces durhamensis NRRL B-3309 (16). Comparison of the phosphonate 
biosynthetic gene clusters from Saccharothrix sp. ST-888 and S. durhamensis B-3309 
revealed a set of five conserved genes (Fig 1.12), which were proposed encode enzymes 
needed for production of DHPPA during valinophos biosynthesis (16). Based on this 
idea, it seems reasonable to suggest that DHPPA is also made by Saccharothrix sp. ST-
888. If so, the published putative phosphonothrixin biosynthetic pathway may be 
incorrect (21) and phosphonothrixin is biosynthesized in a similar fashion to valinophos 
(Fig 1.12) (Fig 4.13) (16). 




 If DHPPA is an intermediate during the biosynthesis of phosphonothrixin, a 
plausible route would involve oxidation to 3-hydroxy-2-oxopropylphosphonic acid 
(2OPPA), which could then be condensed with pyruvate to form phosphonothrixin. 
Moreover, the FtxJ protein, encoded within the gene cluster is homologous to L-iditol 





-dependent reaction (25) (Fig 4.10). 
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Figure 4.10. (Top) Reaction of L-iditol dehydrogenase, also known as sorbitol 
dehydrogenase. This is the putative call for FtxJ using BLAST. (Bottom) Reaction 
catalyzed by FtxJ. The question mark denotes the lack of understanding of the metal-
dependence of FtxJ.  
 With this in mind, I incubated DHPPA with NAD, FtxJ and a mixture of different 
metals, resulting in conversion of DHPPA to a new compound based on 
31
P NMR 
spectroscopy (Fig 4.11). I have putatively assigned this compound 2OPPA based on the 
chemical shifts of the protons associated with the phosphorus atom (Fig 4.12 and Fig 
4.13). Accordingly, only two sets of protons associated with the phosphorus atom and the 
splitting pattern of these protons is simplified (Fig 4.12) in comparison to DHPPA (Fig 
4.9), suggesting a lack of 
3
J-splitting of the protons with one another. In combination 
with the lack of a correlation of a proton displaying a chemical shift indicative of an 
aldehyde (~9-10 ppm) (28), I conclude that the hydroxyl group on the β-carbon is oxidize 




Figure 4.11. (Top) Oxidation of DHPPA to 2OPPA catalyzed by FtxJ. (Bottom) 
31
P 
NMR spectroscopy of the FtxJ reactions to monitor DHPPA consumption. The reactions 
were set up using the following conditions in PBS buffer, pH 7.4: 15 mM DHPPA, 250 
μM NAD+, 10 μM FtxJ, 1x metal mix (50 μM FeCl3, 20 μM CaCl2, 10 μM MnCl2, 10 
μM ZnSO4, 2 μM CoCl2, 2 μM NiCl2, 2 μM CuCl2, 2 μM Na2MoO4, 2 μM Na2SeO3, and 
2 μM H3BO3). Lactate dehydrogenase was added for use as a cofactor-regeneration 







H spectrum of the FtxJ reaction product from Fig 4.11.  Peaks that have 
been labeled correspond to the product of the reaction. The J-coupling of the doublet is 






P HMBC spectrum of the FtxJ reaction zoomed in to show the 




The purified recombinant FtxJ protein has a pink hue, suggesting that the metal 
used by the protein may not be zinc. I initially tested cobalt, but have found that this is 
not the metal required for FtxJ function (Fig 4.14), but upon addition of manganese, we 




P NMR spectrum of FtxJ reactions in the absence of metals and with 
cobalt as the metal. Reaction conditions were set up using the following conditions in 
PBS buffer, pH 7.4: 5-10 mM DHPPA, 250 μM NAD+, 10 μM FtxJ, lactate 
dehydrogenase (4 μg/mL), 10 mM pyruvate, and 10 μM CoCl2 or MnCl2. 
 
4.2.6 FtxE is likely responsible for phosphonothrixin production
5
 
 TPP-dependent enzymes catalyze a number of different reaction including, but 
not limited to, oxidative decarboxylation of α-keto acids, carboligation, and C-C bond 
cleavage (7, 11, 30). If 2OPPA can be condensed with pyruvate utilizing one of the two 
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TPP-dependent enzymes encoded within the gene cluster (FtxE or FtxF), 
phosphonothrixin can be biosynthesized in this one enzymatic step. Therefore, I 
incubated 6x-HIS-tagged FtxE with the reaction product generated using FtxJ (Fig 4.11) 
in the presence of TPP and pyruvate. After 24 hours, I observed the formation of a new 
compound within the reaction mixture (Fig 4.15), which I assigned to be 
phosphonothrixin based on the chemical shifts of the protons correlated with the 
phosphorus atom (Fig 4.16). This suggests that the two-component transketolase, FtxE, is 
involved in the biosynthesis of phosphonothrixin.  
 
Figure 4.15. (Top) Predicted reaction to form phosphonothrixin (Ftx). (Bottom) 
31
P 
NMR spectroscopy of the FtxE reaction to monitor 2OPPA consumption. The reactions 
were set up using the following conditions in PBS buffer, pH 7.4: reaction from Fig 4.12 
pre-treated with Chelex 100 resin to remove excess metals, 10 mM pyruvate, 500 μM 











P HMBC spectrum of the FtxE reaction zoomed in to show the 
phosphonates of interest. This figure goes in conjunction with Fig 4.15. 
4.3 SUMMARY AND OUTLOOK 
 We still do not understand the full biosynthetic pathway to phosphonothrixin, 
though the experiments described here suggest that phosphonothrixin is produced using a 
pathway similar to the valinophos biosynthetic pathway (Fig 4.17) (16). Consistent with 
this hypothesis, oxidation of DHPPA to 2OPPA is readily catalyzed using FtxJ in vitro, 
suggesting this is the native function of this enzyme in vivo. Although our limited NMR 
data highly suggest the product form by FtxJ is 2OPPA (Fig 4.12 and Fig 4.13), the 
product of the reaction needs to be isolated and fully characterized structurally and using 
mass spectrometry.  
 Initial characterizations of the two-component transketolase homolog, FtxE, 
suggest that this protein forms phosphonothrixin (Fig 4.15), although the reaction 
conditions need optimization. There is a possibility that two are missing a cofactor for 
enzyme function of the transketolases as evident by the weak production of 
phosphonothrixin (Fig 4.15). Additionally, there may be an inhibitory component left in 
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the reaction mixture. We used the reaction mixture from Fig 4.11 as the substrate for 
FtxE. It is possible that any remaining metals or excess lactate formed by lactate 
dehydrogenase may be inhibitory for FtxE. Therefore, this reaction needs to be performed 
with pure substrate.  
 Initial data collected for FtxF suggests that this enzyme does not catalyze the 
condensation of phosphonopyruvate with pyruvate (Fig 4.2). It is possible that the 
incorrect keto-acid is being utilized in conjunction with phosphonopyruvate to produce 
the first intermediate proposed by Lin and colleagues, although the mild activity of FtxF 
in the presence of pyruvate (Fig 4.4) suggests that this enzyme likely uses pyruvate as a 
substrate. Thus, the lack of activity with phosphonopyruvate (Fig 4.2) suggests that 
another phosphonic acid may be the physiological substrate. Alternatively, the enzyme 
may be responsible for self-resistance.  
 Many natural product biosynthetic gene clusters encode a resistance gene within 
the cluster to protect the producing organism from the final product or toxic intermediates  
(15). An organism may do this in one of two ways. The first involves the modification of 
toxic intermediates or products so that they are no longer inhibitory. The second involves 
encoding a copy of the target protein within the gene cluster that is resistant to the final 
product (15). One hypothesis that cannot be confirmed or refuted with our data is that 
FtxF may be the resistance protein produced within the phosphonothrixin gene cluster. 
The close molecular mimicry of phosphonothrixin and acetolactate may allow 
phosphonothrixin to target acetolactate synthase (Fig 4.5). We do observe canonical 
acetolactate synthase activity using FtxF (Fig 4.4) and FtxF shares a common ancestor 
136 
 
with bona fide ALS proteins (Fig 4.6); therefore, this enzyme may function as an ALS 
within the producing organism during the biosynthesis of phosphonothrixin. 
 The data presented in this chapter, allow us to propose a biosynthetic pathway for 
this compound (Fig 4.17). We hypothesize that phosphonothrixin and valinophos share 
common first biosynthetic steps to form DHPPA (16). DHPPA will be oxidized using the 
metal-dependent dehydrogenase, FtxJ, to yield 2OPPA (Fig 4.11). FtxE would then 
catalyze the oxidative decarboxylation of pyruvate and the condensation with 2OPPA to 
yield phosphonothrixin (Fig 4.15) (Fig 4.17).  
 
Figure 4.17. (Top) Saccharothrix sp. ST-888 phosphonothrixin gene cluster (21). 
(Bottom) Putative phosphonothrixin biosynthetic pathway. Dashed arrows represent 
hypothesized reactions based on the similarity to valinophos biosynthesis (16).  
 Discovery and characterization of the biosynthesis of phosphonothrixin is an 
important endeavor because of the potential application of phosphonothrixin as an 
herbicide. Due to the rising need of new herbicidal compounds, if the biosynthesis of 
phosphonothrixin can elucidated, we will understand the steps in need of optimization for 
large-scale production of this compound. Additionally, if the target of this compound can 
be identified and the resistance gene is encoded within the biosynthetic gene cluster, 
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crops resembling RoundUp Ready® and LibertyLink® crops may be developed, thus 
helping combat the rise in herbicide resistant weeds that cause massive loss in crops 
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4.4 MATERIALS AND METHODS 
4.4.1 General experimental procedures 
 An Agilent Technologies 600 MHz NMR spectrometer was used to collect all 
nuclear magnetic resonance spectra (NMR) using D2O as a lock solvent. Fisher Scientific 
or Sigma-Aldrich were used for the purchase of all chemicals used in this chapter. 
4.4.2 Cloning and protein purification 
 The FtxF gene from Saccharopolyspora spinosa NRRL 18395 was amplified by 




genomic DNA isolated using an UltraClean® Microbial DNA Isolation Kit (MO-BIO 
Laboratories, San Diego, CA). The plasmid, pET28B, was amplified using primers 
pET28-NdeI-R (5’-CATATGGCTGCCGCGCGGCACCAGGCCGCTG-3’) and 
pET28B-XhoI-F (5’-CTCGAGCACCACCACCACCACCACTGAGATCCGG-3’). 
Uppercase letters represent sequence homologous to the plasmid pET28B. The 
underlined sequence is an inserted restriction enzyme site, and the lowercase letters 
represent sequence homology to the gene to be amplified. The genes for FtxF were 
cloned into pET28B using Gibson Assembly
®
 (New England Biolabs, Ipswich, MA) to 
yield pMNG004. Strains MMG423 was used for expression of RhiH and MMG422 was 
used for the expression of Bf-Ppd.  
143 
 
All of the proteins were isolated using a similar protocol. Briefly, a 5 mL 
overnight culture of BL21 (DE3) cells containing the plasmid of interest was used to 
inoculate a 1 L flask of LB + kanamycin (50 μg/ mL). This culture was grown at 37°C 
until the optical density (OD600) is between 0.6-0.9. Protein production was induced with  
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 100 
μM. Cultures were shaken at 18°C for 16-18 hours. Cells were collected via 
centrifugation and resuspended in lysis buffer (300 mM sodium chloride, 50 mM sodium 
phosphate (dibasic), and 10 mM imidazole, pH 8.0). The cell suspensions were mixed 
with 1 mg/mL lysozyme and 100 units DNase I and incubated on a mutator for 30 
minutes at 4°C. To lyse the cells, each cell suspension was passed through a French Press 
cell disruptor (Thermo Electron Corporation, Waltham, MA) two times at 1000 psi each 
to lyse the cells. The lysed cell suspension was separated via centrifugation for 45 
minutes at 10,000 x g at 4°C. The soluble liquid portion was incubated with 5 mL per 
liter of culture of loose Ni-NTA resin (Thermo Fisher Scientific) for 30 minutes at 4°C. 
The resin was washed with approximately 10 column volumes of wash buffer (300 mM 
sodium chloride, 50 mM sodium phosphate (dibasic), and 20 mM imidazole, pH 8.0) 
until no protein was observed to be eluting from the resin by monitoring absorbance at 
A260 nm. Proteins were eluted using 15 mL of elution buffer (300 mM sodium chloride, 
50 mM sodium phosphate (dibasic), and 250 mM imidazole, pH 8.0). The flow through 
(containing pure protein) was concentrated using a 10 kDa molecular weight Amicon
®
 
Ultra spin filter (EMD Millipore, Burlington, MA). A PD-10 desalting column (GE 
Healthcare Life Sciences, Marlborough, MA) was used to exchange the purified proteins 
into protein storage buffer (200 mM KCl, 50 mM HEPES, and 10% glycerol, pH 7.5). 
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4.4.3 In vitro activity assays using FtxF 
To test whether FtxF could use phosphonopyruvate as a substrate, we incubated 
6xHis-tagged FtxF from Saccharothrix sp. ST-888 with 10 mM phosphoenolpyruvate, 10 
mM sodium pyruvate, 1 mM thiamine pyrophosphate, 50 μg FtxF, and 50 μg RhiH in 50 
mM HEPES buffer pH 7.5 containing 10 mM magnesium chloride. Reactions using 
flavin used 100 μM of either FAD or FMN. The control reaction uses the same 
components as above, with the exception of phosphonopyruvate decarboxylase from 
Bacteroides fragilis being used at a concentration of 50 μg in place of FtxF. To test 
whether FtxF could use DHPPA as a substrate, we incubated 6xHis-tagged FtxF from 
Saccharothrix sp. ST-888 with 1 mM DHPPA, 10 mM sodium pyruvate, 1 mM thiamine 
pyrophosphate, 50 μg FtxF, and 50 μg RhiH in 50 mM HEPES buffer containing 10 mM 
magnesium chloride. Reactions were incubated at 30°C for 12 hours. Enzymes were 
removed from the reactions using a 30 kDa molecular weight Amicon spin filter, and 
D2O was added at a final concentration of 20% for use as a lock solvent for NMR. 
Product formation was determined using 
31
P NMR spectroscopy.  
 To test whether FtxF can function as a canonical acetolactate synthase, we 
incubated 6xHis-tagged FtxF from Saccharothrix sp. ST-888 or S. spinosa NRRL 18395 
with 20 mM sodium pyruvate and 237 μM TPP in 100 mM potassium phosphate buffer, 
pH 7.5 containing 10 mM magnesium chloride. FtxF-ST-888 was used at a concentration 
of 0.1 μM and 1.8 μM, while FtxF-18395 was used at a concentration of 0.1 μM and 3 
μM. Control reactions were performed using 6xHis-tagged AlsS from Bacillus subtilis at 
concentrations of 0.1 μM and 2.5 μM (courtesy of Michael Carter). Reactions were 
incubated at room temperature for 13 hours. Reactions were quenched using 4 μL of 50% 
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sulfuric acid for 25 minutes. 20 μL of the product was added to 280 μL of acetoin 
detection reagent containing 1% α-napthol, 0.1% creatine, and 1 M sodium hydroxide. 
These reactions were incubated for 25 minutes at room temperature. Absorbance at 530 
nm was recorded. A standard curve using 6.25 μM to 200 μM acetoin was made using the 
same protocol. Reactions were repeated in duplicate. 
4.4.4 FtxF phylogeny 
 To construct the maximum-likelihood phylogeny of FtxF that includes only 
proteins with characterized functions, a BLAST search was performed against the 
SwissProt/UniProt database using Saccharothrix sp. ST-888 FtxF as the search query 
(accession number WP_045300935.1) (1). 168 entries were retrieved. To construct the 
maximum-likelihood phylogeny of the closest homologs to FtxF, a BLAST search was 
performed against the nonredundant NCBI database to retrieve 250 sequences (1). 
Sequences were aligned using MAFFT standard settings (17). A maximum-likelihood 
phylogenetic tree was constructed of each dataset using FastTree (29). 
4.4.5 Isolation of phosphonothrixin and DHPPA 
 This project was done in collaboration with Dr. Ryuichi Hirota from Hiroshima 
University. Saccharothrix sp. ST-888 was grown at 30°C for ~7 days in 20 liters of both 
GUBC and R2AS broth, yielding 40 liters of spent media (16). Spent media was dried 
under reduced pressure and resuspended in two liters of water. Methanol was added to a 
final concentration of 75%. Methanol insoluble material was discarded. The 75% 
methanol soluble material was dried under reduced pressure and extracted using 100% 
methanol. Methanol soluble material was dried under reduced pressure rotary evaporation 
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and suspended in 200 mL deionized water. The water-soluble material was passed over 
activated charcoal and material not bound to the activated charcoal was precipitated using 
calcium acetate. Soluble material was separated on a 134.5 cm x 6.4 cm, 4.8 liter resin 
bed Sephadex® G-25 resin size exclusion column (GE Healthcare Life Sciences). 
Fractions containing phosphonic acids were further purified using hydrophilic lipophilic 
balance (HLB) exchange. The fractions containing phosphonic acids were concentrated 
under reduced pressure and resuspended in deionized water. Weak cation exchange was 
performed. The fraction containing phosphonic acids was concentrated and suspended in 
deionized water. This was separated on a 175 cm x 4 cm, 2.4 liter resin bed Sephadex® 
LH-20 resin size exclusion column (GE Healthcare Life Sciences). Fractions containing 
phosphonic acids were concentrated and further purified using IMAC-Fe. I received this 
phosphonate–enriched, partially-purified mixture from Ryuichi Hirota and carried out the 
co-purification of phosphonothrixin and DHPPA. 
 From this point forward, I performed the purification of the phosphonic acids. 
This material was resuspended in 4 mL deionized water and separated on 90 mL 
Sephadex ® G-10 gel filtration column (GE Healthcare Life Sciences), 160 cm x 2 cm. 
The column was run at a flow rate of 100 μL per minute at 4°C using deionized water as 
the solvent. After collection of 40 mL, fractionation of the material was done collecting 
0.5 mL fractions. Phosphonic acids eluted between fractions 21-44. Fractions 31-44 were 
pooled and concentrated under reduced pressure. Sample was resuspended in 5 mM 
sulfuric acid. One eighth of the sample material (100 μL) was injected onto a 300 mm x 
7.8 mm Aminex® HPX-87H ion exclusion chromatography column (Bio-Rad). The 
column was run under isocratic conditions in 5 mM sulfuric acid in deionized water at a 
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flow rate of 0.6 mL / min, collecting fractions every minute (0.6 mL fractions). Fractions 
were neutralized using 1M sodium hydroxide and dried under reduced pressure. Fraction 
ten contained the purified mixture of DHPPA and phosphonothrixin. Fraction ten was 
desalted by passing the material over a 160 cm x 2 cm, 90 mL resin bed, Sephadex® G-
10 column (GE Healthcare Life Sciences) using the same conditions described earlier. 
Fractions containing phosphonic acids were pooled and concentrated under reduced 
pressure. 
 Structure elucidation of the compounds within fraction ten was performed using 
1
H NMR (600 MHz), 
31
P NMR (242 MHz), and 
13
C NMR (150 MHz). All spectra were 































C HSQCAD experiments. These data are consistent with the 
chemical shifts reported for DHPPA (16) and phosphonothrixin (10).  
4.4.6 FtxJ assays 
 Pure N-terminally 6xHis-tagged FtxJ (concentration 10 μM) was incubated with 
15 mM DHPPA, 250 μM NAD+, and metals (50 μM FeCl3, 20 μM CaCl2, 10 μM MnCl2, 
10 μM ZnSO4, 2 μM CoCl2, 2 μM NiCl2, 2 μM CuCl2, 2 μM Na2MoO4, 2 μM Na2SeO3, 
and 2 μM H3BO3) in PBS buffer, pH 7.4 in addition to lactate dehydrogenase 
(concentration 4 μg/mL) and 10 mM pyruvate. The reactions testing for product 
formation in the presence of cobalt used the same conditions as above, with the metal mix 
replaced with 10 μM CoCl2. The reactions were incubated at room temperature for 18 
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hours and stopped by removing the enzyme using a 10 kDa molecular weight Amicon® 
Ultra spin filter (EMD Millipore, Burlington, MA). A small amount (~100 μL volume) of 
Chelex® 100 sodium form resin (Sigma-Aldrich) was added to the reaction to remove 
excess metals. D2O was added to a final concentration of 20% for use as a lock solvent. 
Reaction products were identified via 
1
H NMR (600 MHz) spectroscopy and 
31
P NMR 
(242 MHz) spectroscopy.  
4.4.7 FtxE assays 
 Pure 6xHis-tagged FtxE1 and untagged FtxE2 (concentration 10 μM) were 
incubated with the reaction product of FtxJ with 10 mM pyruvate and 500 μM TPP in 
PBS buffer, pH 7.4. The reactions were stopped after a 24-hour room temperature 
incubation using a 10 kDa molecular weight Amicon® Ultra spin filter (EMD Millipore, 
Burlington, MA). D2O was added as a lock solvent to a final concentration of 20%. 
Reaction products were identified via 
1
H NMR (600 MHz) spectroscopy and 
31
P NMR 
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